<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ZOVIA 1/35E-28- ethynodiol diacetate and ethinyl estradiol 
			 </strong><br><strong>ZOVIA 1/50E-28- ethynodiol diacetate and ethinyl estradiol 
			 </strong><br>Watson Pharma, Inc.<br></p></div>
<h1>
<span class="Italics">Zovia 1/35E-28</span><span class="Italics"><br></span><span class="Italics">Zovia 1/50E-28</span><span class="Italics"><br></span>(Ethynodiol Diacetate and Ethinyl Estradiol Tablets USP)<span class="Italics"><br></span>Revised: August 2006<span class="Italics"><br></span>Rx only<span class="Italics"><br></span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_af2779f9-e076-4719-85c4-93db69af99a5"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Patients should be counseled that this product does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_6ea59f30-b5d5-497a-adb4-45c0ec71cce2"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">DESCRIPTION</span></h1>
<p class="First"><span class="Italics">Zovia 1/35E-28.</span> Each light pink tablet contains 1 mg of ethynodiol diacetate and 35 mcg of ethinyl estradiol, and the inactive ingredients include lactose (anhydrous), magnesium stearate, microcrystalline cellulose, polacrilin potassium, and povidone. In addition, the coloring agents are D&amp;C Red No. 30 Aluminum Lake and D&amp;C Yellow No. 10 Aluminum Lake. Each white tablet in the Zovia 1/35E-28 package is a placebo containing no active ingredients and the inactive ingredients include lactose (anhydrous), magnesium stearate and microcrystalline cellulose.</p>
<p><span class="Italics">Zovia 1/50E-28. </span>Each pink tablet contains 1 mg of ethynodiol diacetate and 50 mcg of ethinyl estradiol, and the inactive ingredients include lactose (anhydrous), magnesium stearate, microcrystalline cellulose, polacrilin potassium, and povidone. In addition, the coloring agents are D&amp;C Red No. 30 Aluminum Lake and D&amp;C Yellow No. 10 Aluminum Lake. Each white tablet in the Zovia 1/50E-28 package is a placebo containing no active ingredients, and the inactive ingredients include lactose (anhydrous), magnesium stearate and microcrystalline cellulose.</p>
<p>The chemical name for ethynodiol diacetate is 19-Nor-17a-pregn-4-en-20-yne-3b,17-diol diacetate, and for ethinyl estradiol it is 19-Nor-17a-pregna-1,3,5(10)-trien-20-yne-3, 17-diol.</p>
<p>The structural formulas are as follows:</p>
<div class="Figure"><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ae3c20e4-8850-4559-9ca3-06a98b3dabab&amp;name=ethynodiol-diacetate-and-ethiny-estradiol-tablets--1.jpg"></div>
<div class="Figure"><img alt="structure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ae3c20e4-8850-4559-9ca3-06a98b3dabab&amp;name=ethynodiol-diacetate-and-ethiny-estradiol-tablets--2.jpg"></div>
<p>Therapeutic class: Oral contraceptive.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_67d6ab02-44f7-43a1-a41b-33e201c9a7a9"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY</span></h1>
<p class="First">Combination oral contraceptives act primarily by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations in the genital tract, including changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which may reduce the likelihood of implantation) may also contribute to contraceptive effectiveness.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_03156467-a024-4323-8e1d-99970c6f92a0"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE</span></h1>
<p class="First">Zovia 1/35E and Zovia 1/50E are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptive products such as Zovia 1/50E, which contain 50 mcg of estrogen, should not be used unless medically indicated.</p>
<p>Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization and progestogen implants and injections, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.</p>
<table>
<caption><span>Table 1. Percentage of women experiencing an <span class="product-label-link" type="condition" conceptid="4307820" conceptname="Unplanned pregnancy">unintended pregnancy</span> during the first year of typical use and the first year of perfect use of contraception and the percentage continuing use at the end of the first year. United States.</span></caption>
<col>
<col>
<col>
<col>
<thead>
<tr class="First">
<td valign="top"> </td>
<td align="center" colspan="2" valign="top"> <span class="Bold">% of women experiencing</span>
</td>
<td align="center" valign="top"> <span class="Bold">% of women</span>
</td>
</tr>
<tr>
<td valign="top"> </td>
<td align="center" colspan="2" valign="top"> <span class="Bold">an <span class="product-label-link" type="condition" conceptid="4307820" conceptname="Unplanned pregnancy">unintended pregnancy</span></span>
</td>
<td align="center" valign="top"> <span class="Bold">continuing</span>
</td>
</tr>
<tr>
<td valign="top"> </td>
<td align="center" colspan="2" valign="top"> <span class="Bold">within the first year of use</span>
</td>
<td align="center" valign="top"> <span class="Bold">use at one</span>
</td>
</tr>
<tr>
<td valign="top"> </td>
<td valign="top"> </td>
<td valign="top"> </td>
<td align="center" valign="top"> <span class="Bold">year </span><span class="Bold"><span class="Italics"><span class="Sup">(C)</span></span></span>
</td>
</tr>
<tr>
<td valign="top"> </td>
<td class="Botrule" valign="top"> </td>
<td class="Botrule" valign="top"> </td>
<td valign="top"> </td>
</tr>
<tr>
<td valign="top"> <span class="Bold">Method</span>
</td>
<td class="Toprule" align="center" valign="top"> <span class="Bold">Typical use </span><span class="Bold"><span class="Italics"><span class="Sup">(A)</span></span></span>
</td>
<td class="Toprule" align="center" valign="top"> <span class="Bold">Perfect use </span><span class="Bold"><span class="Italics"><span class="Sup">(B)</span></span></span>
</td>
<td valign="top"> </td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"> <span class="Bold">(1)</span>
</td>
<td class="Botrule" align="center" valign="top"> <span class="Bold">(2)</span>
</td>
<td class="Botrule" align="center" valign="top"> <span class="Bold">(3)</span>
</td>
<td class="Botrule" align="center" valign="top"> <span class="Bold">(4)</span>
</td>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Botrule" colspan="4" valign="top"> Source: Trussell J, Contraceptive efficacy. In Hatcher RA, Trussell J, Stewart F, Cates W, Stewart GK, Kowal D, Guest F, <span class="Italics">Contraceptive Technology: Seventeenth Revised Edition. </span>New York NY: Irvington Publishers, 1998, in press. <span class="Sup">1</span>
</td></tr>
<tr><td colspan="4" valign="top"> <span class="Italics"><span class="Sup">(A)</span></span> Among <span class="Italics">typical </span>couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason.</td></tr>
<tr><td colspan="4" valign="top"> <span class="Italics"><span class="Sup">(B)</span></span> Among couples who initiate use of a method (not necessarily for the first time) and who use it <span class="Italics">perfectly </span>(both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason.</td></tr>
<tr><td colspan="4" valign="top"> <span class="Italics"><span class="Sup">(C)</span></span>Among couples attempting to avoid pregnancy, the percentage who continue to use a method for one year.</td></tr>
<tr><td colspan="4" valign="top"> <span class="Italics"><span class="Sup">(D)</span></span>The percents becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. Among such populations, about 89% become pregnant within one year. This estimate was lowered slightly (to 85%) to represent the percent who would become pregnant within one year among women now relying on reversible methods of contraception if they abandoned contraception altogether.</td></tr>
<tr><td colspan="4" valign="top"> <span class="Italics"><span class="Sup">(E)</span></span> Foams, creams, gels, vaginal suppositories, and vaginal film.</td></tr>
<tr><td colspan="4" valign="top"> <span class="Italics"><span class="Sup">(F)</span></span>Cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal body temperature in the post-ovulatory phases.</td></tr>
<tr><td colspan="4" valign="top"> <span class="Italics"><span class="Sup">(G)</span></span> With spermicidal cream or jelly.</td></tr>
<tr><td colspan="4" valign="top"> <span class="Italics"><span class="Sup">(H)</span></span> Without spermicides.</td></tr>
<tr><td colspan="4" valign="top"> <span class="Italics"><span class="Sup">(I)</span></span> The treatment schedule is one dose within 72 hours after unprotected intercourse and a second dose 12 hours after the first dose. The Food and Drug Administration has declared the following brands of oral contraceptives to be safe and effective for emergency contraception: Ovral (1 dose is 2 white pills), Alesse (1 dose is 5 pink pills), Nordette or Levlen (1 dose is 2 light-orange pills), Lo/Ovral (1 dose is 4 white pills), Triphasil or Tri-Levlen (1 dose is 4 yellow pills).</td></tr>
<tr class="Last"><td colspan="4" valign="top"> <span class="Italics"><span class="Sup">(J)</span></span> However, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is reduced, bottle feeds are introduced, or the baby reaches six months of age.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td valign="top"> Chance <span class="Italics"><span class="Sup">(D)</span></span>
</td>
<td align="center" valign="top"> 85</td>
<td align="center" valign="top"> 85</td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top"> Spermicides <span class="Italics"><span class="Sup">(E)</span></span>
</td>
<td align="center" valign="top"> 26</td>
<td align="center" valign="top"> 6</td>
<td align="center" valign="top"> 40</td>
</tr>
<tr>
<td valign="top"> Periodic abstinence</td>
<td align="center" valign="top"> 25</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> 63</td>
</tr>
<tr>
<td valign="top">   Calendar</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> 9</td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top">   Ovulation method</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> 3</td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top">   Sympto-thermal <span class="Italics"><span class="Sup">(F)</span></span>
</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> 2</td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top">   Post-ovulation</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> 1</td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top"> Withdrawal</td>
<td align="center" valign="top"> 19</td>
<td align="center" valign="top"> 4</td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top"> Cap <span class="Italics"><span class="Sup">(G)</span></span>
</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top">   Parous women</td>
<td align="center" valign="top"> 40</td>
<td align="center" valign="top"> 26</td>
<td align="center" valign="top"> 42</td>
</tr>
<tr>
<td valign="top">   Nulliparous women</td>
<td align="center" valign="top"> 20</td>
<td align="center" valign="top"> 9</td>
<td align="center" valign="top"> 56</td>
</tr>
<tr>
<td valign="top"> Sponge</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top">   Parous women</td>
<td align="center" valign="top"> 40</td>
<td align="center" valign="top"> 20</td>
<td align="center" valign="top"> 42</td>
</tr>
<tr>
<td valign="top">   Nulliparous women</td>
<td align="center" valign="top"> 20</td>
<td align="center" valign="top"> 9</td>
<td align="center" valign="top"> 56</td>
</tr>
<tr>
<td valign="top"> Diaphragm <span class="Italics"><span class="Sup">(G)</span></span>
</td>
<td align="center" valign="top"> 20</td>
<td align="center" valign="top"> 6</td>
<td align="center" valign="top"> 56</td>
</tr>
<tr>
<td valign="top"> Condom <span class="Italics"><span class="Sup">(H)</span></span>
</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top">   Female (Reality)</td>
<td align="center" valign="top"> 21</td>
<td align="center" valign="top"> 5</td>
<td align="center" valign="top"> 56</td>
</tr>
<tr>
<td valign="top">   Male</td>
<td align="center" valign="top"> 14</td>
<td align="center" valign="top"> 3</td>
<td align="center" valign="top"> 61</td>
</tr>
<tr>
<td valign="top"> Pill</td>
<td align="center" valign="top"> 5</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> 71</td>
</tr>
<tr>
<td valign="top">   Progestin only</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> 0.5</td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top">   Combined</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> 0.1</td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top"> IUD</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top">   Progesterone T</td>
<td align="center" valign="top"> 2.0</td>
<td align="center" valign="top"> 1.5</td>
<td align="center" valign="top"> 81</td>
</tr>
<tr>
<td valign="top">   Copper T 380A</td>
<td align="center" valign="top"> 0.8</td>
<td align="center" valign="top"> 0.6</td>
<td align="center" valign="top"> 78</td>
</tr>
<tr>
<td valign="top">   LNg 20</td>
<td align="center" valign="top"> 0.1</td>
<td align="center" valign="top"> 0.1</td>
<td align="center" valign="top"> 81</td>
</tr>
<tr>
<td valign="top"> Injection (Depo-Provera)</td>
<td align="center" valign="top"> 0.3</td>
<td align="center" valign="top"> 0.3</td>
<td align="center" valign="top"> 70</td>
</tr>
<tr>
<td valign="top"> Implant (Norplant</td>
<td align="center" valign="top"> 0.05</td>
<td align="center" valign="top"> 0.05</td>
<td align="center" valign="top"> 88</td>
</tr>
<tr>
<td valign="top">   and Norplant-2)</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top"> Female sterilization</td>
<td align="center" valign="top"> 0.5</td>
<td align="center" valign="top"> 0.5</td>
<td align="center" valign="top"> 100</td>
</tr>
<tr>
<td valign="top"> Male sterilization</td>
<td align="center" valign="top"> 0.15</td>
<td align="center" valign="top"> 0.10</td>
<td align="center" valign="top"> 100</td>
</tr>
<tr>
<td class="Botrule" valign="top"> </td>
<td class="Botrule" valign="top"> </td>
<td class="Botrule" valign="top"> </td>
<td class="Botrule" valign="top"> </td>
</tr>
<tr><td class="Toprule" colspan="4" valign="top"> <span class="Bold">Emergency Contraceptive Pills:</span> Treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%. <span class="Italics"><span class="Sup">(I)</span></span>
</td></tr>
<tr class="Last"><td class="Botrule" colspan="4" valign="top"> <span class="Bold">Lactational <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span> Method:</span> LAM is a highly effective, <span class="Italics">temporary </span>method of contraception. <span class="Italics"><span class="Sup">(J)</span></span>
</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_b8566a8e-48b7-400b-9bec-72e16871a240"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS</span></h1>
<p class="First">Oral contraceptives should not be used in women who have the following conditions:</p>
<ul class="Disk">
<li><p class="First"><span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span> or thromboembolic disorders</p></li>
<li><p class="First">A past history of deep vein <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> or thromboembolic disorders</p></li>
<li><p class="First">Cerebral vascular disease, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, or <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, or a past history of these conditions</p></li>
<li><p class="First">Known or suspected carcinoma of the breast, or a history of this condition</p></li>
<li><p class="First">Known or suspected carcinoma of the female reproductive organs or suspected estrogen-dependent neoplasia, or a history of these conditions</p></li>
<li><p class="First">Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></p></li>
<li><p class="First">History of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> of pregnancy or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> with prior oral contraceptive use</p></li>
<li><p class="First">Past or present, benign or <span class="product-label-link" type="condition" conceptid="201519" conceptname="Primary malignant neoplasm of liver">malignant liver tumors</span></p></li>
<li><p class="First">Known or suspected pregnancy</p></li>
</ul>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_ee9b925f-1e21-4a33-ba10-456bb2f59aef"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">WARNINGS</span></h1>
<table>
<col>
<col>
<tbody class="Headless"><tr class="First Last">
<td class="Lrule" valign="top"> <span class="Bold">Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.</span>
</td>
<td class="Rrule" valign="top"> </td>
</tr></tbody>
</table>
<p class="First">The use of oral contraceptives is associated with increased risk of several serious conditions including venous and arterial <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, thrombotic and <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span> or other liver lesions, and <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>. The risk of morbidity and mortality increases significantly in the presence of other risk factors such as <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus.</p>
<p>Practitioners prescribing oral contraceptives should be familiar with the following information relating to these and other risks.</p>
<p>The information contained herein is principally based on studies carried out in patients who used oral contraceptives with formulations containing higher amounts of estrogens and progestogens than those in common use today. The effect of long-term use of the oral contraceptives with lesser amounts of both estrogens and progestogens remains to be determined.</p>
<p>Throughout this labeling, epidemiological studies reported are of two types: retrospective casecontrol studies and prospective cohort studies. Case-control studies provide an estimate of the relative risk of a disease, which is defined as the <span class="Italics">ratio </span>of the incidence of a disease among oral contraceptive users to that among nonusers. The relative risk (or odds ratio) does not provide information about the actual clinical occurrence of a disease. Cohort studies provide a measure of both the relative risk and the attributable risk. The latter is the <span class="Italics">difference </span>in the incidence of disease between oral contraceptive users and nonusers. The attributable risk does provide information about the actual occurrence or incidence of a disease in the subject population. For further information, the reader is referred to a text on epidemiological methods.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e8f0530f-56cf-436b-ba48-18599514a0d9"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold">1. Thromboembolic disorders and other vascular problems.</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2e34b1e3-85c1-4788-ab61-8432f022b762"></a><a name="section-6.1.1"></a><p></p>
<h3><span class="Italics"><span class="Bold">a. <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span>.</span></span></h3>
<p class="First">An increased risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> has been associated with oral contraceptive use.<span class="Sup">2-21</span> This increased risk is primarily in smokers or in women with other underlying risk factors for <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> such as <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, and <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>. The relative risk for <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> in current oral contraceptive users has been estimated to be 2 to 6. The risk is very low under the age of 30. However, there is the possibility of a risk of cardiovascular disease even in very young women who take oral contraceptives.</p>
<p>Smoking in combination with oral contraceptive use has been reported to contribute substantially to the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> in women in their mid-thirties or older, with smoking accounting for the majority of excess cases.<span class="Sup">22</span> Mortality rates associated with circulatory disease have been shown to increase substantially in smokers, especially in those 35 years of age and older among women who use oral contraceptives (see Figure 1, Table 2).</p>
<p><span class="Bold">Figure 1.</span> Circulatory disease mortality rates per 100,000 woman-years by age, smoking status, and oral contraceptive use.<span class="Sup">14</span></p>
<div class="Figure"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ae3c20e4-8850-4559-9ca3-06a98b3dabab&amp;name=ethynodiol-diacetate-and-ethiny-estradiol-tablets--3.jpg"></div>
<p>Adapted from Layde and Beral.<span class="Sup">14</span></p>
<p>Oral contraceptives may compound the effects of well-known cardiovascular risk factors such as <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemias</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, age, cigarette smoking, and <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>. In particular, some progestogens decrease HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span><span class="Sup">23-31</span> and cause <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span>, while estrogens may create a state of <span class="product-label-link" type="condition" conceptid="4307509" conceptname="Hyperinsulinism">hyperinsulinism</span>.<span class="Sup">32</span> Oral contraceptives have been shown to increase blood pressure among some users (see <a href="#LINK_34ff3297-6ca1-40fb-b93c-2c9e0aa637f4">WARNING No. 9</a>). Similar effects on risk factors have been associated with an increased risk of heart disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0d922bae-1b86-4e5f-83ba-33332aabf3a9"></a><a name="section-6.1.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">b. <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">Thromboembolism</span>.</span></span></h3>
<p class="First">An increased risk of thromboembolic and thrombotic disease associated with the use of oral contraceptives is well established.<span class="Sup">17, 33-51</span> Case-control studies have estimated the relative risk to be 3 for the first episode of superficial <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>, 4 to 11 for <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> or <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, and 1.5 to 6 for women with predisposing conditions for venous thromboembolic disease.<span class="Sup">34-37, 45, 46</span> Cohort studies have shown the relative risk to be somewhat lower, about 3 for new cases (subjects with no past history of <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> or <span class="product-label-link" type="condition" conceptid="312349" conceptname="Venous varices">varicose veins</span>) and about 4.5 for new cases requiring hospitalization.<span class="Sup">42, 47, 48</span> The risk of venous thromboembolic disease associated with oral contraceptives is not related to duration of use.</p>
<p>A two- to seven-fold increase in relative risk of postoperative thromboembolic complications has been reported with the use of oral contraceptives.<span class="Sup">38, 39</span> The relative risk of <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> in women who have predisposing conditions is about twice that of women without such medical conditions.<span class="Sup">43</span> If feasible, oral contraceptives should be discontinued at least 4 weeks prior to and for 2 weeks after elective surgery of a type associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, and also during and following prolonged immobilization. Since the immediate postpartum period is also associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, oral contraceptives should be started no earlier than 4 to 6 weeks after delivery in women who elect not to breast feed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_76ee8abc-0e27-4af8-9268-d8bf7829062a"></a><a name="section-6.1.3"></a><p></p>
<h3><span class="Bold"><span class="Italics">c. Cerebrovascular diseases.</span></span></h3>
<p class="First">Both the relative and attributable risks of cerebrovascular events (thrombotic and <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic strokes</span>) have been reported to be increased with oral contraceptive use,<span class="Sup">14, 17, 18, 34, 42, 46, 52-59</span> although, in general, the risk was greatest among older (over 35 years), hypertensive women who also smoked. <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> was reported to be a risk factor for both users and nonusers, for both types of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, while smoking increased the risk for <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic strokes</span>.</p>
<p>In one large study,<span class="Sup">52</span> the relative risk for <span class="product-label-link" type="condition" conceptid="4159140" conceptname="Thrombotic stroke">thrombotic stroke</span> was reported as 9.5 times greater in users than in nonusers. It ranged from 3 for normotensive users to 14 for users with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.<span class="Sup">54</span> The relative risk for <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> was reported to be 1.2 for <span class="product-label-link" type="condition" conceptid="4222303" conceptname="Non-smoker">nonsmokers</span> who used oral contraceptives, 1.9 to 2.6 for smokers who did not use oral contraceptives, 6.1 to 7.6 for smokers who used oral contraceptives, 1.8 for normotensive users, and 25.7 for users with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. The risk is also greater in older women and among smokers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_530961c1-dbbf-400d-baa9-e6910afe964d"></a><a name="section-6.1.4"></a><p></p>
<h3><span class="Bold"><span class="Italics">d. Dose-related risk of vascular disease with oral contraceptives.</span></span></h3>
<p class="First">A positive association has been reported between the amount of estrogen and progestogen in oral contraceptives and the risk of vascular disease.<span class="Sup">41, 43, 53, 59-64</span> A decline in serum high density lipoproteins (HDL) has been reported with many progestogens.<span class="Sup">23-31</span> A decline in serum high density lipoproteins has been associated with an increased incidence of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>.<span class="Sup">65</span> Because estrogens increase HDL-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, the net effect of an oral contraceptive depends on the balance achieved between doses of estrogen and progestogen and the nature and absolute amount of progestogens used in the contraceptives. The amount of both steroids should be considered in the choice of an oral contraceptive.</p>
<p>Minimizing exposure to estrogen and progestogen is in keeping with good principles of therapeutics. For any particular estrogen-progestogen combination, the dosage regimen prescribed should be one that contains the least amount of estrogen and progestogen that is compatible with a low failure rate and the needs of the individual patient. New acceptors of oral contraceptives should be started on preparations containing the lowest estrogen content that produces satisfactory results in the individual.</p>
<p>Products containing 50 mcg estrogen should be used only when medically indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_63ec7e54-fcfa-489f-8cd9-5e2ed186560c"></a><a name="section-6.1.5"></a><p></p>
<h3><span class="Bold"><span class="Italics">e. Persistence of risk of vascular disease.</span></span></h3>
<p class="First">There are three studies that have shown persistence of risk of vascular disease for users of oral contraceptives. In a study in the United States, the risk of developing <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> after discontinuing oral contraceptives persisted for at least 9 years for women 40-49 years old who had used oral contraceptives for 5 or more years, but this increased risk was not demonstrated in other age groups.<span class="Sup">16</span> Another American study reported former use of oral contraceptives was significantly associated with increased risk of <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>.<span class="Sup">57</span> In another study, in Great Britain, the risk of developing non-rheumatic heart disease plus <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="441874" conceptname="Cerebral thrombosis">cerebral thrombosis</span>, and <span class="product-label-link" type="condition" conceptid="373503" conceptname="Transient cerebral ischemia">transient ischemic attacks</span> persisted for at least 6 years after discontinuation of oral contraceptives, although the excess risk was small.<span class="Sup">14, 18, 66</span> It should be noted that these studies were performed with oral contraceptive formulations containing 50 mcg or more of estrogens.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_df995f36-8ae4-4b2a-8369-fcda7089426d"></a><a name="section-6.2"></a><p></p>
<h2><span class="Bold">2. Estimates of mortality from contraceptive use.</span></h2>
<p class="First">One study<span class="Sup">67</span> gathered data from a variety of sources that have estimated the mortality rates associated with different methods of contraception at different ages (Table 2). These estimates include the combined risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> associated with contraceptive methods plus the risk attributable to pregnancy in the event of method failure. Each method of contraception has its specific benefits and risks. The study concluded that, with the exception of oral contraceptive users 35 and older who smoke and 40 or older who do not smoke, mortality associated with all methods of birth control is low and below that associated with childbirth. The observation of a possible increase in risk of mortality with age for oral contraceptive users is based on data gathered in the 1970’s, but not reported until 1983.<span class="Sup">67</span> However, current clinical practice involves the use of lower estrogen dose formulations combined with careful restriction of oral contraceptive use to women who do not have the various risk factors listed in this labeling.</p>
<p>Because of these changes in practice and, also, because of some limited new data that suggest that the risk of cardiovascular disease with the use of oral contraceptives may now be less than previously observed,<span class="Sup">48, 152</span> the Fertility and Maternal Health Drugs Advisory Committee was asked to review the topic in 1989. The Committee concluded that, although cardiovascular disease risks may be increased with oral contraceptive use after age 40 in healthy nonsmoking women (even with the newer low-dose formulations), there are greater potential health risks associated with pregnancy in older women and with the alternative surgical and medical procedures that may be necessary if such women do not have access to effective and acceptable means of contraception.</p>
<p>Therefore, the Committee recommended that the benefits of oral contraceptive use by healthy nonsmoking women over 40 may outweigh the possible risks. Of course, older women, as all women who take oral contraceptives, should take the lowest possible dose formulation that is effective.</p>
<table>
<caption><span>Table 2. Annual number of birth-related or method-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> associated with control of fertility per 100,000 nonsterile women, by fertility control method according to age.<span class="Sup">67</span></span></caption>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<thead>
<tr class="First">
<td colspan="2" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" colspan="2" valign="top"> <span class="Bold">Age</span>
</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td colspan="2" valign="top"> </td>
<td class="Botrule" align="center" valign="top"> </td>
<td class="Botrule" align="center" valign="top"> </td>
<td class="Botrule" align="center" valign="top"> </td>
<td class="Botrule" align="center" valign="top"> </td>
<td class="Botrule" align="center" valign="top"> </td>
<td class="Botrule" align="center" valign="top"> </td>
</tr>
<tr class="Last">
<td colspan="2" valign="top"> <span class="Bold">Method of control</span>
</td>
<td class="Toprule" align="center" valign="top"> <span class="Bold">15-19</span>
</td>
<td class="Toprule" align="center" valign="top"> <span class="Bold">20-24</span>
</td>
<td class="Toprule" align="center" valign="top"> <span class="Bold">25-29</span>
</td>
<td class="Toprule" align="center" valign="top"> <span class="Bold">30-34</span>
</td>
<td class="Toprule" align="center" valign="top"> <span class="Bold">35-39</span>
</td>
<td class="Toprule" align="center" valign="top"> <span class="Bold">40-44</span>
</td>
</tr>
</thead>
<tfoot>
<tr class="First"><td colspan="8" valign="top"> * <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> are birth-related</td></tr>
<tr><td colspan="8" valign="top"> ** <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> are method-related</td></tr>
<tr class="Last"><td colspan="8" valign="top">  Adapted from Ory.<span class="Bold"><span class="Sup">67</span></span>
</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td colspan="2" valign="top"> No fertility control methods*</td>
<td align="center" valign="top"> 7.0</td>
<td align="center" valign="top"> 7.4</td>
<td align="center" valign="top"> 9.1</td>
<td align="center" valign="top"> 14.8</td>
<td align="center" valign="top"> 25.7</td>
<td align="center" valign="top"> 28.2</td>
</tr>
<tr>
<td colspan="2" valign="top"> Oral contraceptives</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td align="right" valign="top"> </td>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="4222303" conceptname="Non-smoker">nonsmoker</span>**</td>
<td align="center" valign="top"> 0.3</td>
<td align="center" valign="top"> 0.5</td>
<td align="center" valign="top"> 0.9</td>
<td align="center" valign="top"> 1.9</td>
<td align="center" valign="top"> 13.8</td>
<td align="center" valign="top"> 31.6</td>
</tr>
<tr>
<td align="right" valign="top"> </td>
<td valign="top"> smoker**</td>
<td align="center" valign="top"> 2.2</td>
<td align="center" valign="top"> 3.4</td>
<td align="center" valign="top"> 6.6</td>
<td align="center" valign="top"> 13.5</td>
<td align="center" valign="top"> 51.1</td>
<td align="center" valign="top"> 117.2</td>
</tr>
<tr>
<td colspan="2" valign="top"> IUD**</td>
<td align="center" valign="top"> 0.8</td>
<td align="center" valign="top"> 0.8</td>
<td align="center" valign="top"> 1.0</td>
<td align="center" valign="top"> 1.0</td>
<td align="center" valign="top"> 1.4</td>
<td align="center" valign="top"> 1.4</td>
</tr>
<tr>
<td colspan="2" valign="top"> Condom*</td>
<td align="center" valign="top"> 1.1</td>
<td align="center" valign="top"> 1.6</td>
<td align="center" valign="top"> 0.7</td>
<td align="center" valign="top"> 0.2</td>
<td align="center" valign="top"> 0.3</td>
<td align="center" valign="top"> 0.4</td>
</tr>
<tr>
<td colspan="2" valign="top"> Diaphragm/Spermicide*</td>
<td align="center" valign="top"> 1.9</td>
<td align="center" valign="top"> 1.2</td>
<td align="center" valign="top"> 1.2</td>
<td align="center" valign="top"> 1.3</td>
<td align="center" valign="top"> 2.2</td>
<td align="center" valign="top"> 2.8</td>
</tr>
<tr class="Last">
<td colspan="2" valign="top"> Periodic abstinence*</td>
<td align="center" valign="top"> 2.5</td>
<td align="center" valign="top"> 1.6</td>
<td align="center" valign="top"> 1.6</td>
<td align="center" valign="top"> 1.7</td>
<td align="center" valign="top"> 2.9</td>
<td align="center" valign="top"> 3.6</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4d673ca2-cee6-40f4-8382-f6376534b2d9"></a><a name="section-6.3"></a><p></p>
<h2><span class="Bold">3. Carcinoma of the breast and reproductive organs.</span></h2>
<p class="First">Numerous epidemiological studies have been performed on the incidence of breast, endometrial, ovarian, and cervical cancer in women using oral contraceptives. While there are conflicting reports, many studies suggest that the use of oral contraceptives is not associated with an overall increase in the risk of developing breast cancer.<span class="Sup">17,40,68–78</span> Other studies, however, have reported an increased risk overall,<span class="Sup">153–155</span> or in certain subgroups. In these studies, increased risk has been associated with long duration of use, use beginning at a young age, use before the first term pregnancy, use by those who had an <span class="product-label-link" type="condition" conceptid="4185404" conceptname="Early menarche">early menarche</span>, those who had a positive family history of breast cancer, or in nulliparas.<span class="Sup">79–102,151,156–162</span> These risks have been surveyed in two books<span class="Sup">163–164</span> and in review articles.<span class="Sup">85,99,153,165–167</span></p>
<p>Some studies suggested that oral contraceptive use was associated with an increase in the risk of <span class="product-label-link" type="condition" conceptid="198572" conceptname="Cervical intraepithelial neoplasia">cervical intraepithelial neoplasia</span>, <span class="product-label-link" type="condition" conceptid="4093447" conceptname="Dysplasia">dysplasia</span>, erosion, carcinoma, or microglandular <span class="product-label-link" type="condition" conceptid="4093447" conceptname="Dysplasia">dysplasia</span> in some populations of women.<span class="Sup">17, 50, 103-115</span> However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors.</p>
<p>In spite of many studies of the relationship between oral contraceptive use and breast and cervical cancers, a cause and effect relationship has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c703456e-d869-4e95-816f-dfa81929046f"></a><a name="section-6.4"></a><p></p>
<h2><span class="Bold">4. <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Hepatic neoplasia</span>.</span></h2>
<p class="First">Benign <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatic adenomas</span> and other <span class="product-label-link" type="condition" conceptid="4104000" conceptname="Lesion of liver">hepatic lesions</span> have been associated with oral contraceptive use,<span class="Sup">116-121</span> although the incidence of such benign tumors is rare in the United States. Indirect calculations have estimated the attributable risk to be in the range of 3.3 cases per 100,000 for users, a risk that increases after 4 or more years of use.<span class="Sup">120</span> Rupture of benign, <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatic adenomas</span> or other lesions may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> through intraabdominal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>. Therefore, such lesions should be considered in women presenting with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="192438" conceptname="Abdominal mass">abdominal mass</span>, or <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>. About one quarter of the cases presented because of <span class="product-label-link" type="condition" conceptid="192438" conceptname="Abdominal mass">abdominal masses</span>; up to one half had signs and symptoms of acute intraperitoneal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.<span class="Sup">121</span> Diagnosis may prove difficult.</p>
<p>Studies from the U.S.,<span class="Sup">122, 150</span> Great Britain,<span class="Sup">123, 124</span> and Italy<span class="Sup">125</span> have shown an increased risk of hepatocellular carcinoma in long-term (&gt;8 years; relative risk of 7-20) oral contraceptive users. However, these cancers are rare in the United States, and the attributable risk (the excess incidence) of liver cancers in oral contraceptive users approaches less than 1 per 1,000,000 users.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b67c341c-1da0-4742-a49c-a2c2a486f0e1"></a><a name="section-6.5"></a><p></p>
<h2><span class="Bold">5. Ocular lesions.</span></h2>
<p class="First">There have been reports of retinal <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> and other ocular lesions associated with the use of oral contraceptives. Oral contraceptives should be discontinued if there is unexplained, gradual or sudden, partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>; onset of <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">proptosis</span> or <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>; <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>; or any evidence of retinal vascular lesions. Appropriate diagnostic and therapeutic measures should be undertaken immediately.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6d999e51-0c08-491a-8608-d209cf232dac"></a><a name="section-6.6"></a><p></p>
<h2><span class="Bold">6. Oral contraceptive use before or during pregnancy.</span></h2>
<p class="First">Extensive epidemiological studies have revealed no increased risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in women who have used oral contraceptives prior to pregnancy.<span class="Sup">126, 129</span> The majority of recent studies also do not suggest a teratogenic effect, particularly insofar as cardiac anomalies and <span class="product-label-link" type="condition" conceptid="73307" conceptname="Transverse deficiency of lower limb">limb reduction defects</span> are concerned,<span class="Sup">126, 129</span> when the pill is taken inadvertently during early pregnancy.</p>
<p>The administration of oral contraceptives to induce <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> should not be used as a test for pregnancy. Oral contraceptives should not be used during pregnancy to treat threatened or habitual abortion. It is recommended that for any patient who has missed two consecutive periods, pregnancy should be ruled out before continuing oral contraceptive use. If the patient has not adhered to the prescribed schedule, the possibility of pregnancy should be considered at the time of the first missed period and further use of oral contraceptives should be withheld until pregnancy has been ruled out. Oral contraceptive use should be discontinued if pregnancy is confirmed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0851518d-58c0-4760-b172-f54314a4cf56"></a><a name="section-6.7"></a><p></p>
<h2><span class="Bold">7. <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span>.</span></h2>
<p class="First">Earlier studies reported an increased lifetime relative risk of gallbladder surgery in users of oral contraceptives and estrogens.<span class="Sup">40, 42, 53, 70</span> More recent studies, however, have shown that the relative risk of developing <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> among oral contraceptive users may be minimal.<span class="Sup">130-132</span> The recent findings of minimal risk may be related to the use of oral contraceptive formulations containing lower doses of estrogens and progestogens.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3adc691a-7b4c-4e1e-af4f-265d5d240ff7"></a><a name="section-6.8"></a><p></p>
<h2><span class="Bold">8. Carbohydrate and lipid metabolic effects.</span></h2>
<p class="First">Oral contraceptives have been shown to cause a decrease in glucose tolerance in a significant percentage of users.<span class="Sup">32</span> This effect has been shown to be directly related to estrogen dose.<span class="Sup">133</span> Progestogens increase insulin secretion and create <span class="product-label-link" type="condition" conceptid="4168924" conceptname="Drug resistance to insulin">insulin resistance</span>, the effect varying with different progestational agents.<span class="Sup">32, 134</span> However, in the nondiabetic woman, oral contraceptives appear to have no effect on fasting blood glucose. Because of these demonstrated effects, prediabetic and diabetic women should be carefully observed while taking oral contraceptives.</p>
<p>Some women may have persistent <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> while on the pill. As discussed earlier (see <span class="Bold">WARNINGS</span><a href="#LINK_2e34b1e3-85c1-4788-ab61-8432f022b762">1a</a> and <a href="#LINK_530961c1-dbbf-400d-baa9-e6910afe964d">1d</a>), changes in serum triglycerides and lipoprotein levels have been reported in oral contraceptive users.<span class="Sup">23-31, 135, 136</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_34ff3297-6ca1-40fb-b93c-2c9e0aa637f4"></a><a name="section-6.9"></a><p></p>
<h2><span class="Bold">9. Elevated blood pressure.</span></h2>
<p class="First">An increase in blood pressure has been reported in women taking oral contraceptives<span class="Sup">50, 53, 137-139</span> and this increase is more likely in older oral contraceptive users<span class="Sup">137</span> and with extended duration of use.<span class="Sup">53</span> Data from the Royal College of General Practitioners<span class="Sup">138</span> and subsequent randomized trials have shown that the incidence of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> increases with increasing concentrations of progestogens.</p>
<p>Women with a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>-related disease, or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span><span class="Sup">139</span> should be encouraged to use another method of contraception. If such women elect to use oral contraceptives, they should be monitored closely and if significant elevation of blood pressure occurs, oral contraceptives should be discontinued. For most women, elevated blood pressure will return to normal after stopping oral contraceptives,<span class="Sup">137</span> and there is no difference in the occurrence of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> among ever- and never-users.<span class="Sup">140</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e9a622a1-0ea0-4e1e-9c7f-341e1d700acf"></a><a name="section-6.10"></a><p></p>
<h2><span class="Bold">10. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>.</span></h2>
<p class="First">The onset or exacerbation of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> or the development of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> of a new pattern that is recurrent, persistent, or severe requires discontinuation of oral contraceptives and evaluation of the cause.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ba9c2d57-e0b5-4f3d-8a15-6ade5a728903"></a><a name="section-6.11"></a><p></p>
<h2><span class="Bold">11. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> irregularities.</span></h2>
<p class="First">Breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and spotting are sometimes encountered in patients on oral contraceptives, especially during the first three months of use. Nonhormonal causes should be considered and adequate diagnostic measures taken to rule out malignancy or pregnancy in the event of breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, as in the case of any abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>. If a pathologic basis has been excluded, time alone or a change to another formulation may solve the problem. In the event of <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, pregnancy should be ruled out. Some women may encounter post-pill <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> or <span class="product-label-link" type="condition" conceptid="442274" conceptname="Oligomenorrhea">oligomenorrhea</span>, especially when such a condition was pre-existent.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_53e7ebb8-8a28-48cf-8fd4-3576a4008e39"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">PRECAUTIONS</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9e991177-bb85-42fa-b078-4692f4bb25bf"></a><a name="section-7.1"></a><p></p>
<h2><span class="Bold">1. Physical examination and follow-up.</span></h2>
<p class="First">It is good medical practice for all women to have annual history and physical examinations, including women using oral contraceptives. The physical examination, however, may be deferred until after initiation of oral contraceptives if requested by the woman and judged appropriate by the clinician. The physical examination should include special reference to blood pressure, breasts, abdomen, and pelvic organs, including cervical <span class="product-label-link" type="condition" conceptid="45771295" conceptname="Cytology">cytology</span>, and relevant laboratory tests. In case of undiagnosed, persistent, or recurrent abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>, appropriate measures should be conducted to rule out malignancy. Women with a strong family history of breast cancer or who have breast <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> should be monitored with particular care.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_760f1506-011d-44d8-ad91-cbd03fa0a86f"></a><a name="section-7.2"></a><p></p>
<h2><span class="Bold">2. Lipid disorders.</span></h2>
<p class="First">Women who are being treated for <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemias</span> should be followed closely if they elect to use oral contraceptives. Some progestogens may elevate LDL levels and may render the control of <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemias</span> more difficult.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_61628e7f-0560-48cc-a75e-415073a017f1"></a><a name="section-7.3"></a><p></p>
<h2><span class="Bold">3. Liver function.</span></h2>
<p class="First">If <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> develops in any woman receiving oral contraceptives, they should be discontinued. Steroids may be poorly metabolized in patients with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span> and should be administered with caution in such patients. <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic jaundice</span> has been reported after combined treatment with oral contraceptives and troleandomycin. Hepatotoxicity following a combination of oral contraceptives and cyclosporine has also been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_df0fb578-f9f6-4176-9cea-d3d0daec0970"></a><a name="section-7.4"></a><p></p>
<h2><span class="Bold">4. <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span>.</span></h2>
<p class="First">Oral contraceptives may cause some degree of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. They should be prescribed with caution, and only with careful monitoring, in patients with conditions that might be aggravated by <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, such as <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> syndrome, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, or cardiac, hepatic, or renal dysfunction.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_cfbad2f3-64db-4a59-b8bd-a4404807625b"></a><a name="section-7.5"></a><p></p>
<h2><span class="Bold">5. <span class="product-label-link" type="condition" conceptid="4305081" conceptname="Emotional problems">Emotional disorders</span>.</span></h2>
<p class="First">Women with a history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> should be carefully observed and the drug discontinued if <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> recurs to a serious degree.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_093e75ac-d5e4-48fd-a893-fcf541be5a70"></a><a name="section-7.6"></a><p></p>
<h2><span class="Bold">6. Contact lenses.</span></h2>
<p class="First">Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_51e3dcb6-def0-408a-9fd5-705952d1e301"></a><a name="section-7.7"></a><p></p>
<h2><span class="Bold">7. Drug interactions.</span></h2>
<p class="First">Reduced efficacy and increased incidence of breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and menstrual irregularities have been associated with concomitant use of rifampin. A similar association, though less marked, has been suggested for barbiturates, phenylbutazone, phenytoin sodium, and possibly with griseofulvin, ampicillin, and tetracyclines. Administration of troglitazone concomitantly with a combination oral contraceptive (estrogen and progestin) reduced the plasma concentrations of both hormones by approximately 30%. This could result in loss of contraceptive efficacy.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="LINK_52f1a0b2-b475-4960-a516-a7c28d601498"></a><a name="section-7.8"></a><p></p>
<h2><span class="Bold">8. Laboratory test interactions.</span></h2>
<p class="First">Certain endocrine and liver function tests and blood components may be affected by oral contraceptives:</p>
<ol class="LittleAlpha">
<li><p class="First">Increased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> and factors VII, VIII, IX and X; decreased antithrombin III; increased platelet aggregability.</p></li>
<li><p class="First">Increased <span class="product-label-link" type="condition" conceptid="4188578" conceptname="Thyroxine binding globulin">thyroid binding globulin</span> (TBG), leading to increased circulating total thyroid hormone as measured by protein-bound iodine (PBI), T<span class="Sub">4</span> by column or by radioimmunoassay. Free T<span class="Sub">3</span> resin uptake is decreased, reflecting the elevated TBG; free T<span class="Sub">4</span> concentration is unaltered.</p></li>
<li><p class="First">Other binding proteins may be elevated in the serum.</p></li>
<li><p class="First">Sex-steroid binding globulins are increased and result in elevated levels of total circulating sex steroids and corticoids; however, free or biologically active levels remain unchanged.</p></li>
<li><p class="First">Triglycerides and phospholipids may be increased.</p></li>
<li><p class="First">Glucose tolerance may be decreased.</p></li>
<li><p class="First">Serum folate levels may be depressed. This may be of clinical significance if a woman becomes pregnant shortly after discontinuing oral contraceptives.</p></li>
<li><p class="First">Increased sulfobromophthalein and other abnormalities in liver function tests may occur.</p></li>
<li><p class="First">Plasma levels of trace minerals may be altered.</p></li>
<li><p class="First">Response to the metyrapone test may be reduced.</p></li>
</ol>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_3c7ce7b4-a0cf-49ec-8351-2631bd40884b"></a><a name="section-7.9"></a><p></p>
<h2><span class="Bold">9. Carcinogenesis.</span></h2>
<p class="First">(See <a href="#LINK_ee9b925f-1e21-4a33-ba10-456bb2f59aef">WARNINGS</a>.)</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_0840866e-5006-4dc0-88fb-225bfea8807c"></a><a name="section-7.10"></a><p></p>
<h2><span class="Bold">10. Pregnancy.</span></h2>
<p class="First"><span class="Bold">Pregnancy Category X.</span> (See <span class="Bold"><a href="#LINK_b8566a8e-48b7-400b-9bec-72e16871a240">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#LINK_ee9b925f-1e21-4a33-ba10-456bb2f59aef">WARNINGS</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_de2f2d3a-3a2c-4eaf-b580-d871596e03db"></a><a name="section-7.11"></a><p></p>
<h2><span class="Bold">11. Nursing mothers.</span></h2>
<p class="First">Small amounts of oral contraceptive steroids have been identified in the milk of nursing mothers<span class="Sup">141-143</span> and a few adverse effects on the child have been reported, including <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>. In addition, oral contraceptives given in the postpartum period may interfere with lactation by decreasing the quantity and quality of breast milk. If possible, the nursing mother should be advised not to use oral contraceptives, but to use other forms of contraception until she has completely weaned her child.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_5d117eb7-6ef3-4619-9248-cf8b292f5389"></a><a name="section-7.12"></a><p></p>
<h2><span class="Bold">12. Pediatric use.</span></h2>
<p class="First">Safety and efficacy of Zovia have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents under the age of 16 and for users 16 years and older. Use of this product before <span class="product-label-link" type="condition" conceptid="4061459" conceptname="Menarche">menarche</span> is not indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_971f3274-ecd5-4947-8061-fbcab20cc363"></a><a name="section-7.13"></a><p></p>
<h2><span class="Bold">13. Venereal diseases.</span></h2>
<p class="First">Oral contraceptives are of no value in the prevention or treatment of venereal disease. The prevalence of cervical <span class="Italics">Chlamydia trachomatis</span> and <span class="Italics">Neisseria gonorrhoeae</span> in oral contraceptive users is increased several-fold.<span class="Sup">144, 145</span> It should not be assumed that oral contraceptives afford protection against <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> from chlamydia.<span class="Sup">144</span> Patients should be counseled that this product does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>.</p>
</div>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_12aeb14f-12f4-446e-af99-35d961380f8f"></a><a name="section-7.14"></a><p></p>
<h2><span class="Bold">14. General.</span></h2>
<ol class="LittleAlpha">
<li><p class="First">The pathologist should be advised of oral contraceptive therapy when relevant specimens are submitted.</p></li>
<li><p class="First">Treatment with oral contraceptives may mask the onset of the <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">climacteric</span>. (See <a href="#LINK_ee9b925f-1e21-4a33-ba10-456bb2f59aef">WARNINGS</a> regarding risks in this age group.)</p></li>
</ol>
<p class="First"><span class="Bold">INFORMATION FOR THE PATIENT</span></p>
<p>See <a href="#LINK_ec24cb5b-ec0d-4dd4-8e3c-df1e59a5f5ff">patient labeling</a> printed below.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_243eb96d-27b1-43ca-bd53-988e6dfec497"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS</span></h1>
<p class="First">An increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives (see <span class="Bold"><a href="#LINK_ee9b925f-1e21-4a33-ba10-456bb2f59aef">WARNINGS</a></span>):</p>
<ul class="Disk">
<li><p class="First"><span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span> and <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span></p></li>
<li><p class="First">Arterial <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="4134723" conceptname="Coronary artery thrombosis">coronary thrombosis</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Cerebral hemorrhage</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="441874" conceptname="Cerebral thrombosis">Cerebral thrombosis</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span></p></li>
<li><p class="First">Benign and <span class="product-label-link" type="condition" conceptid="201519" conceptname="Primary malignant neoplasm of liver">malignant liver tumors</span>, and other <span class="product-label-link" type="condition" conceptid="4104000" conceptname="Lesion of liver">hepatic lesions</span></p></li>
</ul>
<p>There is evidence of an association between the following conditions and the use of oral contraceptives, although additional confirmatory studies are needed:</p>
<ul class="Disk">
<li><p class="First">Mesenteric <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span></p></li>
<li><p class="First">Neuro-ocular lesions (e.g., retinal <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> and <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>)</p></li>
</ul>
<p>The following adverse reactions have been reported in patients receiving oral contraceptives and are believed to be drug-related:</p>
<ul class="Disk">
<li><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal symptoms</span> (such as <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span> and <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>)</p></li>
<li><p class="First">Breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></p></li>
<li><p class="First">Spotting</p></li>
<li><p class="First">Change in menstrual flow</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span> during or after use</p></li>
<li><p class="First">Temporary <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> after discontinuation of use</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">Chloasma</span> or <span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">melasma</span>, which may persist</p></li>
<li><p class="First">Breast changes: <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, enlargement, secretion</p></li>
<li><p class="First">Change in weight (increase or decrease)</p></li>
<li><p class="First">Change in cervical erosion or secretion</p></li>
<li><p class="First">Diminution in lactation when given immediately postpartum</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic jaundice</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> (allergic)</p></li>
<li><p class="First">Mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></p></li>
<li><p class="First">Reduced tolerance to carbohydrates</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">Vaginal candidiasis</span></p></li>
<li><p class="First">Change in corneal curvature (steepening)</p></li>
<li><p class="First">Intolerance to contact lenses</p></li>
</ul>
<p>The following adverse reactions or conditions have been reported in users of oral contraceptives and the association has been neither confirmed nor refuted:</p>
<ul class="Disk">
<li><p class="First"><span class="product-label-link" type="condition" conceptid="439081" conceptname="Premenstrual tension syndrome">Premenstrual syndrome</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataracts</span></p></li>
<li><p class="First">Changes in appetite</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">Cystitis</span>-like syndrome</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">Hirsutism</span></p></li>
<li><p class="First">Loss of scalp hair</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">Erythema nodosum</span></p></li>
<li><p class="First">Hemorrhagic <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruption</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginitis</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">Porphyria</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired renal function</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">Hemolytic uremic syndrome</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></p></li>
<li><p class="First">Changes in libido</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span></p></li>
<li><p class="First">Budd-Chiari syndrome</p></li>
<li><p class="First">Endocervical <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> or <span class="product-label-link" type="condition" conceptid="376132" conceptname="Ectropion">ectropion</span></p></li>
</ul>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_14a7b6ba-d5d8-42e0-87c5-388de1a9a14a"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">OVERDOSAGE</span></h1>
<p class="First">Serious ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children.<span class="Sup">180, 181</span> Overdosage may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> may occur in females.</p>
<p><span class="Bold">NON-CONTRACEPTIVE HEALTH BENEFITS</span></p>
<p>The following non-contraceptive health benefits related to the use of oral contraceptives are supported by epidemiological studies that largely utilized oral contraceptive formulations containing estrogen doses exceeding 35 mcg of ethinyl estradiol or 50 mcg of mestranol.<span class="Sup">148, 149</span></p>
<p><span class="Italics">Effects on menses:</span></p>
<ul class="Disk">
<li><p class="First">Increased menstrual cycle regularity</p></li>
<li><p class="First">Decreased blood loss and decreased risk of iron-<span class="product-label-link" type="condition" conceptid="4280354" conceptname="Nutritional anemia">deficiency anemia</span></p></li>
<li><p class="First">Decreased frequency of <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span></p></li>
</ul>
<p><span class="Italics">Effects related to inhibition of ovulation:</span></p>
<ul class="Disk">
<li><p class="First">Decreased risk of functional <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">ovarian cysts</span></p></li>
<li><p class="First">Decreased risk of ectopic pregnancies</p></li>
</ul>
<p><span class="Italics">Effects from long-term use:</span></p>
<ul class="Disk">
<li><p class="First">Decreased risk of fibroadenomas and fibrocystic disease of the breast</p></li>
<li><p class="First">Decreased risk of acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span></p></li>
<li><p class="First">Decreased risk of endometrial cancer</p></li>
<li><p class="First">Decreased risk of ovarian cancer</p></li>
<li><p class="First">Decreased risk of <span class="product-label-link" type="condition" conceptid="197236" conceptname="Uterine leiomyoma">uterine fibroids</span></p></li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_26e6d8a6-92fd-45cc-9543-1cc6da9b8a29"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION</span></h1>
<p class="First">To achieve maximum contraceptive effectiveness, oral contraceptives must be taken exactly as directed and at intervals of 24 hours.</p>
<p>IMPORTANT: If the Sunday start schedule is selected, the patient should be instructed to use an additional method of protection until after the first week of administration <span class="Italics">in the initial cycle.</span></p>
<p>The possibility of ovulation and conception prior to initiation of use should be considered.</p>
<p><span class="Bold">Zovia 1/35E-28</span></p>
<p><span class="Bold">Zovia 1/50E-28</span></p>
<p><span class="Bold">Dosage Schedules</span></p>
<p>The Zovia 1/35E-28 and Zovia 1/50E-28 tablet dispensers contain 21 colored active tablets arranged in three numbered rows of 7 tablets each, followed by a fourth row of 7 white placebo tablets.</p>
<p>Days of the week are printed above the tablets, starting with Sunday on the left.</p>
<p><span class="Bold">28-Day Schedule:</span> For a DAY 1 START, count the first day of menstrual flow as Day 1 and the first tablet (light pink or pink) is then taken on Day 1. For a SUNDAY START when menstrual flow begins on or before Sunday, the first tablet (light pink or pink) is taken on that day. With either a DAY 1 START or SUNDAY START, 1 tablet (light pink or pink) is taken each day at the same time for 21 days. Then the white tablets are taken for 7 days, whether <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> has stopped or not. After all 28 tablets have been taken, whether <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> has stopped or not, the same dosage schedule is repeated beginning on the following day.</p>
<p><span class="Bold">Special notes</span></p>
<p><span class="Italics">Spotting, breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.</span> If spotting (<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> insufficient to require a pad), breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (heavier <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> similar to a menstrual flow), or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> occurs the patient should continue taking her tablets as directed. The incidence of spotting, breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> is minimal, most frequently occurring in the first cycle. Ordinarily spotting or breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> will stop within a week. Usually the patient will begin to cycle regularly within two or three courses of tablet-taking. In the event of spotting or breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> organic causes should be borne in mind. (See <a href="#LINK_ba9c2d57-e0b5-4f3d-8a15-6ade5a728903">WARNING No. 11</a>.)</p>
<p><span class="Italics">Missed menstrual periods.</span> Withdrawal flow will normally occur 2 or 3 days after the last active tablet is taken. Failure of <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> ordinarily does not mean that the patient is pregnant, providing the dosage schedule has been correctly followed. (See <a href="#LINK_6d999e51-0c08-491a-8608-d209cf232dac">WARNING No. 6</a>.)</p>
<p>If the patient has <span class="Italics">not </span>adhered to the prescribed dosage regimen, the possibility of pregnancy should be considered after the first missed period, and oral contraceptives should be withheld until pregnancy has been ruled out.</p>
<p>If the patient has adhered to the prescribed regimen and misses two consecutive periods, pregnancy should be ruled out before continuing the contraceptive regimen.</p>
<p>The first intermenstrual interval after discontinuing the tablets is usually prolonged; consequently, a patient for whom a 28-day cycle is usual might not begin to menstruate for 35 days or longer. Ovulation in such prolonged cycles will occur correspondingly later in the cycle. Post-treatment cycles after the first one, however, are usually typical for the individual woman prior to taking tablets. (See <a href="#LINK_ba9c2d57-e0b5-4f3d-8a15-6ade5a728903">WARNING No. 11</a>.)</p>
<p><span class="Italics">Missed tablets.</span> If a woman misses taking one active tablet, the missed tablet should be taken as soon as it is remembered. In addition, the next tablet should be taken at the usual time. If two consecutive active tablets are missed in week 1 or week 2 of the dispenser, the dosage should be doubled for the next 2 days. The regular schedule should then be resumed, but an additional method of protection must be used as backup for the next 7 days if she has sex during that time or she may become pregnant.</p>
<p>If two consecutive active tablets are missed in week 3 of the dispenser or three consecutive active tablets are missed during any of the first 3 weeks of the dispenser, direct the patient to do one of the following: Day 1 Starters should discard the rest of the dispenser and begin a new dispenser that same day; Sunday Starters should continue to take 1 tablet daily until Sunday, discard the rest of the dispenser and begin a new dispenser that same day. The patient may not have a period this month; however, if she has missed two consecutive periods, pregnancy should be ruled out. An additional method of protection must be used as a backup for the next 7 days after the tablets are missed if she has sex during that time or she may become pregnant.</p>
<p>While there is little likelihood of ovulation if only one active tablet is missed, the possibility of spotting or breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is increased and should be expected if two or more successive active tablets are missed. However, the possibility of ovulation increases with each successive day that scheduled active tablets are missed.</p>
<p>If one or more placebo tablets of Zovia 1/35E-28 or Zovia 1/50E-28 are missed, the Zovia 1/35E-28 or Zovia 1/50E-28 schedule should be resumed on the eighth day after the last colored tablet was taken. Omission of placebo tablets in the 28-tablet courses does not increase the possibility of conception provided that this schedule is followed.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_29f30cbe-0686-40b0-9185-6b8573cfcad7"></a><a name="section-11"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED</span></h1>
<p class="First"><span class="Bold">Zovia 1/35E:</span> Each light pink Zovia 1/35E tablet is round in shape, unscored, debossed with <span class="Bold">WATSON 383</span> and contains 1 mg of ethynodiol diacetate and 35 mcg of ethinyl estradiol.</p>
<p>Zovia 1/35E-28 is packaged in cartons of three (NDC 52544-383-31) and six (NDC 52544-383-28) tablet dispensers. Each dispenser contains 21 light pink tablets and 7 white placebo tablets. (Placebo tablets have a debossed <span class="Bold">WATSON</span> on one side and <span class="Bold">P</span> on the other side.)</p>
<p><span class="Bold">Zovia 1/50E:</span> Each pink Zovia 1/50E tablet is round in shape, unscored, debossed with <span class="Bold">WATSON 384</span> and contains 1 mg of ethynodiol diacetate and 50 mcg of ethinyl estradiol.</p>
<p>Zovia 1/50E-28 is packaged in cartons of three (NDC 52544-384-31) and six (NDC 52544-384-28) tablet dispensers. Each dispenser contains 21 pink tablets and 7 white placebo tablets. (Placebo tablets have a debossed <span class="Bold">WATSON</span> on one side and <span class="Bold">P</span> on the other side.)</p>
<p>Store at 20°-25°C (68°-77°F). [See USP controlled room temperature.]</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_ed52d7a8-e5c8-4fd7-8415-f6fe0376bf51"></a><a name="section-12"></a><p></p>
<h1><span class="Bold">REFERENCES</span></h1>
<p class="First"><span class="Bold">1.</span> Hatcher RA, et al. <span class="Italics">Contraceptive Technology: Seventeenth Revised Edition.</span> New York, NY, 1998. <span class="Bold">1a. </span><span class="Italics">Physicians’ Desk Reference.</span> 47th ed. Oradell, NJ: Medical Economics Co Inc; 1993;2598-2601. <span class="Bold">2.</span> Mann JI, et al. <span class="Italics">Br Med J.</span> 1975; 2 (May 3):241. <span class="Bold">3.</span> Mann JI, et al. <span class="Italics">Br Med J.</span> 1975;3(Sept 13):631. <span class="Bold">4.</span> Mann JI, et al. <span class="Italics">Br Med J.</span> 1975;2(May 3):245. <span class="Bold">5.</span> Mann JI, et al. <span class="Italics">Br Med J.</span> 1976;2(Aug 21):445. <span class="Bold">6.</span> Arthes FG, et al. <span class="Italics">Chest.</span> 1976;70 (Nov):574. <span class="Bold">7.</span> Jain AK, <span class="Italics">Am J Obstet Gynecol.</span> 1976;301(Oct 1):126 and <span class="Italics">Stud Fam Plann.</span> 1977;8(March):50. <span class="Bold">8.</span> Ory HW. <span class="Italics">JAMA.</span> 1977;237(June 13):2619. <span class="Bold">9.</span> Jick H, et al. <span class="Italics">JAMA.</span> 1978;239(April 3):1403, 1407. <span class="Bold">10.</span> Jick H, et al. <span class="Italics">JAMA.</span> 1978;240(Dec 1):2548. <span class="Bold">11.</span> Shapiro S, et al. <span class="Italics">Lancet.</span> 1979;1(April 7):743. <span class="Bold">12.</span> Rosenberg L, et al. <span class="Italics">Am J Epidemiol.</span> 1980;111(Jan):59. <span class="Bold">13.</span> Krueger DE, et al. <span class="Italics">Am J Epidemiol.</span> 1980;111 (June):655. <span class="Bold">14.</span> Layde P, et al. <span class="Italics">Lancet.</span> 1981;1(March 7):541. <span class="Bold">15.</span> Adam SA, et al. <span class="Italics">Br J Obstet Gynaecol.</span> 1981;88(Aug):838. <span class="Bold">16.</span> Slone D, et al. <span class="Italics">N Engl J Med.</span> 1981;305 (Aug 20):420. <span class="Bold">17.</span> Ramcharan S, et al. <span class="Italics">The Walnut Creek Contraceptive Drug Study.</span> Vol 3. US Govt Ptg Off. 1981; and <span class="Italics">J Reprod Med.</span> 1980;25(Dec):346. <span class="Bold">18.</span> Layde PM, et al. <span class="Italics">J R Coll Gen Pract.</span> 1983;33(Feb):75. <span class="Bold">19.</span> Rosenberg L, et al. <span class="Italics">JAMA.</span> 1985;253(May 24/31):2965. <span class="Bold">20.</span> Mant D, et al. <span class="Italics">J Epidemiol Community Health.</span> 1987;41 (Sept):215. <span class="Bold">21.</span> Croft P, et al. <span class="Italics">Br Med J. </span>1989;298 (Jan 21):165. <span class="Bold">22.</span> Goldbaum GM, et al. <span class="Italics">JAMA.</span> 1987;258(Sept 11):1339. <span class="Bold">23.</span> Bradley DD, et al. <span class="Italics">N Engl J Med.</span> 1978;299(July 6):17. <span class="Bold">24.</span> Tikkanen MJ. <span class="Italics">J Reprod Med. </span>1986;31(Sept suppl):898. <span class="Bold">25.</span> Lipson A, et al. <span class="Italics">Contraception.</span> 1986;34(Aug):121. <span class="Bold">26.</span> Burkman RT, et al. <span class="Italics">Obstet Gynecol.</span> 1988; 71(Jan):33. <span class="Bold">27.</span> Knopp RH, <span class="Italics">J Reprod Med.</span> 1986;31(Sept Suppl):913. <span class="Bold">28.</span> Krauss RM, et al. <span class="Italics">Am J Obstet Gynecol.</span> 1983;145(Feb 15):446. <span class="Bold">29.</span> Wahl P, et al. <span class="Italics">N Engl J Med.</span> 1983;308(April 14):862. <span class="Bold">30.</span>Wynn V, et al. <span class="Italics">Am J Obstet Gynecol. </span>1982;142(March 15):766. <span class="Bold">31.</span> LaRosa JC. <span class="Italics">J Reprod Med.</span> 1986;31(Sept suppl):906. <span class="Bold">32.</span> Wynn V, et al. <span class="Italics">J Reprod Med.</span> 1986;31(Sept Suppl):892. <span class="Bold">33.</span> Royal College of General Practitioners. <span class="Italics">J R Coll Gen Pract.</span> 1967;13(May):267. <span class="Bold">34.</span> Inman WHW, et al. <span class="Italics">Br Med J.</span> 1968;2(April 27):193. <span class="Bold">35.</span> Vessey MP, et al. <span class="Italics">Br Med J.</span> 1968;2(April 27):199. <span class="Bold">36.</span> Vessey MP, et al. <span class="Italics">Br Med J.</span> 1969;2(June 14):651. <span class="Bold">37.</span> Sartwell PE, et al. <span class="Italics">Am J Epidemiol.</span> 1969;90(Nov):365. <span class="Bold">38.</span> Vessey MP, et al. <span class="Italics">Br Med J.</span> 1970;3(July 18):123. <span class="Bold">39.</span> Greene GR, et al. <span class="Italics">Am J Public Health.</span> 1972;62(May):680. <span class="Bold">40.</span> Boston Collaborative Drug Surveillance Programme. <span class="Italics">Lancet. </span>1973;1(June 23):1399. <span class="Bold">41.</span> Stolley PD, et al. <span class="Italics">Am J Epidemiol.</span> 1975;102(Sept):197. <span class="Bold">42.</span> Vessey MP, et al. <span class="Italics">J Biosoc Sci. </span>1976;8(Oct):373. <span class="Bold">43.</span> Kay CR, <span class="Italics">J R Coll Gen Pract.</span> 1978;28(July):393. <span class="Bold">44.</span> Petitti DB, et al. <span class="Italics">Am J Epidemiol.</span> 1978;108 (Dec):480. <span class="Bold">45.</span> Maquire MG, et al. <span class="Italics">Am J Epidemiol.</span> 1979;110(Aug):188. <span class="Bold">46.</span> Petitti DB, et al. <span class="Italics">JAMA.</span> 1979;242(Sept 14):1150. <span class="Bold">47.</span> Porter JB, et al. <span class="Italics">Obstet Gynecol.</span> 1982;59(March):299. <span class="Bold">48.</span> Porter JB, et al. <span class="Italics">Obstet Gynecol.</span> 1985;66(July):1. <span class="Bold">49.</span> Vessey MP, et al. <span class="Italics">Br Med J. </span>1986;292(Feb 22):526. <span class="Bold">50.</span> Hoover R, et al. <span class="Italics">Am J Public Health.</span> 1978;68(April):335. <span class="Bold">51.</span> Vessey MP, <span class="Italics">Br J Fam Plann. </span>1980;6(Oct suppl):1. <span class="Bold">52.</span> Collaborative Group for the Study of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> in Young Women. <span class="Italics">N Engl J Med.</span> 1973;288(April 26):871. <span class="Bold">53.</span> Royal College of General Practitioners. <span class="Italics">Oral Contraceptives and Health. </span>New York, NY: Pitman Publ Corp; May 1974. <span class="Bold">54.</span> Collaborative Group for the Study of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> in Young Women. <span class="Italics">JAMA.</span> 1975;231(Feb 17):718. <span class="Bold">55.</span> Beral V. <span class="Italics">Lancet.</span> 1976;2(Nov 13):1047. <span class="Bold">56.</span> Vessey MP, et al. <span class="Italics">Lancet.</span> 1977;2(Oct 8):731; and 1981;1(March 7):549. <span class="Bold">57.</span> Petitti DB, et al. <span class="Italics">Lancet.</span> 1978;2(July 29):234. <span class="Bold">58.</span> Inman WHW. <span class="Italics">Br Med J.</span> 1979;2(Dec 8):1468. <span class="Bold">59.</span> Vessey MP, et al. <span class="Italics">Br Med J. </span>1984; 289(Sept 1):530. <span class="Bold">60.</span> Inman WHW, et al. <span class="Italics">Br Med J. </span>1970;2(April 25):203. <span class="Bold">61.</span> Meade TW, et al. <span class="Italics">Br Med J.</span> 1980;280(May 10):1157. <span class="Bold">62.</span> Böttiger LE, et al. <span class="Italics">Lancet.</span> 1980;1(May 24):1097. <span class="Bold">63.</span> Kay CR. <span class="Italics">Am J Obstet Gynecol.</span> 1982;142(March 15):762. <span class="Bold">64.</span> Vessey MP, et al. <span class="Italics">Br Med J.</span> 1986;292(Feb 22):526. <span class="Bold">65.</span> Gordon T, et al. <span class="Italics">Am J Med.</span> 1977;62(May):707. <span class="Bold">66.</span> Beral V, et al. <span class="Italics">Lancet. </span>1977;2(Oct 8):727. <span class="Bold">67.</span> Ory H. <span class="Italics">Fam Plann Perspect. </span>1983;15(March-April):57. <span class="Bold">68.</span> Arthes FG, et al. <span class="Italics">Cancer.</span> 1971;28 (Dec):1391. <span class="Bold">69.</span> Vessey MP, et al. <span class="Italics">Br Med J.</span> 1972;3(Sept 23):719. <span class="Bold">70.</span> Boston Collaborative Drug Surveillance Program. <span class="Italics">N Engl J Med.</span> 1974;290(Jan 3):15. <span class="Bold">71.</span> Vessey MP, et al. <span class="Italics">Lancet.</span> 1975;1(April 26):941. <span class="Bold">72.</span> Casagrande J, et al. <span class="Italics">J Natl Cancer Inst.</span> 1976;56(April):839. <span class="Bold">73.</span> Kelsey, JL, et al. <span class="Italics">Am J Epidemiol. </span>1978;107(March):236. <span class="Bold">74.</span> Kay CR, <span class="Italics">Br Med J.</span> 1981;282(June 27):2089. <span class="Bold">75.</span> Vessey MP, et al. <span class="Italics">Br Med J.</span> 1981;282(June 27):2093. <span class="Bold">76.</span> The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. Oral contraceptive use and the risk of breast cancer. <span class="Italics">N Engl J Med.</span> 1986;315(Aug 14):405. <span class="Bold">77.</span> Paul C, et al. <span class="Italics">Br Med J. </span>1986; 293 (Sept 20):723. <span class="Bold">78.</span> Miller DR, et al. <span class="Italics">Obstet Gynecol.</span> 1986;68(Dec):863. <span class="Bold">79.</span> Pike MC, et al. <span class="Italics">Lancet.</span> 1983;2(Oct 22):926. <span class="Bold">80.</span> McPherson K, et al. <span class="Italics">Br J Cancer.</span> 1987;56(Nov):653. <span class="Bold">81.</span> Hoover R, et al. <span class="Italics">N Engl J Med.</span> 1976;295(Aug 19):401. <span class="Bold">82.</span> Lees AW, et al. <span class="Italics">Int J Cancer.</span> 1978;22(Dec):700. <span class="Bold">83.</span> Brinton LA, et al. <span class="Italics">J Natl Cancer Inst.</span> 1979;62(Jan):37. <span class="Bold">84.</span> Black MM. <span class="Italics">Pathol Res Pract.</span> 1980;166:491; and <span class="Italics">Cancer.</span> 1980;46(Dec):2747; and <span class="Italics">Cancer.</span> 1983;51(June):2147. <span class="Bold">85.</span> Thomas DB. <span class="Italics">JNCI.</span> 1993;85 (March 3):359. <span class="Bold">86.</span> Brinton LA, et al. <span class="Italics">Int J Epidemiol.</span> 1982;11(Dec):316. <span class="Bold">87.</span> Harris NV, et al. <span class="Italics">Am J Epidemiol. </span>1982;116(Oct):643. <span class="Bold">88.</span> Jick H, et al. <span class="Italics">Am J Epidemiol.</span> 1980;112(Nov):577. <span class="Bold">89.</span> McPherson K, et al. <span class="Italics">Lancet.</span> 1983;2(Dec 17):1414. <span class="Bold">90.</span> Hoover R, et al. <span class="Italics">J Natl Cancer Inst.</span> 1981; 67(Oct):815. <span class="Bold">91.</span> Jick H, et al. <span class="Italics">Am J Epidemiol.</span> 1980; 112(Nov):586. <span class="Bold">92.</span> Meirik O, et al. <span class="Italics">Lancet.</span> 1986;2 (Sept 20):650. <span class="Bold">93.</span> Fasal E, et al. <span class="Italics">J Natl Cancer Inst.</span> 1975;55(Oct):767. <span class="Bold">94.</span> Paffenbarger RS, et al. <span class="Italics">Cancer.</span> 1977;39(April suppl):1887. <span class="Bold">95.</span> Stadel BV, et al. <span class="Italics">Contraception.</span> 1988;38(Sept):287. <span class="Bold">96.</span> Miller DR, et al. <span class="Italics">Am J Epidemiol.</span> 1989;129(Feb):269. <span class="Bold">97.</span> Kay CR, et al. <span class="Italics">Br J Cancer.</span> 1988;58(Nov):675. <span class="Bold">98.</span> Miller DR, et al. <span class="Italics">Obstet Gynecol.</span> 1986;68(Dec):863. <span class="Bold">99.</span> Hulka BS, et al. <span class="Italics">Cancer.</span> 1994;74(August 1 suppl):1111. <span class="Bold">100.</span> Chilver CED, et al. <span class="Italics">Br J Cancer.</span> 1994;67(May):922. <span class="Bold">101.</span> Huggins GR, et al. <span class="Italics">Fertil Steril.</span> 1987;47(May):733. <span class="Bold">102.</span> Pike MC, et al. <span class="Italics">Br J Cancer.</span> 1981;43(Jan):72. <span class="Bold">103.</span> Ory H, et al. <span class="Italics">Am J Obstet Gynecol.</span> 1976;124(March 15):573. <span class="Bold">104.</span> Stern E, et al. <span class="Italics">Science.</span> 1977;196(June 24):1460. <span class="Bold">105.</span> Pertiz E, et al. <span class="Italics">Am J Epidemiol. </span>1977;106(Dec):462. <span class="Bold">106.</span> Ory HW, et al. In: Garattini S, Berendes H, eds. <span class="Italics">Pharmacology of Steroid Contraceptive Drugs. </span>New York, NY: Raven Press; 1977:211-224. <span class="Bold">107.</span> Meisels A, et al. <span class="Italics">Cancer.</span> 1977;40(Dec):3076. <span class="Bold">108.</span> Goldacre MJ, et al. <span class="Italics">Br Med J. </span>1978;1(March 25):748. <span class="Bold">109.</span> Swan SH, et al. <span class="Italics">Am J Obstet Gynecol.</span> 1981;139(Jan 1):52. <span class="Bold">110.</span> Vessey MP, et al. <span class="Italics">Lancet.</span> 1983;2(Oct 22):930. <span class="Bold">111.</span> Dallenbach-Hellweg G. <span class="Italics">Pathol Res Pract. </span>1984;179:38. <span class="Bold">112.</span> Thomas DB, et al. <span class="Italics">Br Med J. </span>1985;290(March 30):961. <span class="Bold">113.</span> Brinton LA, et al. <span class="Italics">Int J Cancer.</span> 1986;38(Sept):339. <span class="Bold">114.</span> Ebeling K, et al. <span class="Italics">Int J Cancer.</span> 1987;39(April):427. <span class="Bold">115.</span> Beral V, et al. <span class="Italics">Lancet.</span> 1988;2(Dec 10):1331. <span class="Bold">116.</span> Baum JK, et al. <span class="Italics">Lancet.</span> 1973;2(Oct 27):926. <span class="Bold">117.</span> Edmondson HA, et al. <span class="Italics">N Engl J Med.</span> 1976;294(Feb 26):470. <span class="Bold">118.</span> Bein NN, et al. <span class="Italics">Br J Surg.</span> 1977;64(June):433. <span class="Bold">119.</span> Klatskin G. <span class="Italics">Gastroenterology.</span> 1977;73(Aug):386. <span class="Bold">120.</span> Rooks JB, et al. <span class="Italics">JAMA.</span> 1979;242(Aug 17):644. <span class="Bold">121.</span> Sturtevant FM. In: Moghissi K, ed. <span class="Italics">Controversies in Contraception,</span> Baltimore, MD; Williams &amp; Wilkins; 1979:93-150. <span class="Bold">122.</span> Henderson BE, et al. <span class="Italics">Br J Cancer.</span> 1983;48(July):437. <span class="Bold">123.</span> Neuberger J, et al. <span class="Italics">Br Med J.</span> 1986;292(May 24):1355. <span class="Bold">124.</span> Forman D, et al. <span class="Italics">Br Med J.</span> 1986;292(May 24):1357. <span class="Bold">125.</span> La Vecchia C, et al. <span class="Italics">Br J Cancer. </span>1989;59(March):460. <span class="Bold">126.</span> Savolainen E, et al. <span class="Italics">Am J Obstet Gynecol </span>1981;140(July 1):521. <span class="Bold">127.</span> Ferencz C, et al. <span class="Italics">Teratology. </span>1980;21(April):225. <span class="Bold">128.</span> Rothman KJ, et al. <span class="Italics">Am J Epidemiol.</span> 1979;109(April):433. <span class="Bold">129.</span> Harlap S, et al. <span class="Italics">Obstet Gynecol. </span>1980;55(April):447.<span class="Bold">130.</span> Layde PM, et al. <span class="Italics">J Epidemiol Community Health.</span> 1982;36(Dec):274. <span class="Bold">131.</span> Rome Group for the Epidemiology and Prevention of <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">Cholelithiasis</span> (GREPCO). <span class="Italics">Am J Epidemiol.</span> 1984;119(May):796. <span class="Bold">132.</span> Strom BL, et al. <span class="Italics">Clin Pharmacol Ther.</span> 1986;39(March):335. <span class="Bold">133.</span> Wynn V. In: Bardin CE, et al, eds. <span class="Italics">Progesterone and Progestins.</span> New York, NY: Raven Press; 1983:395-410. <span class="Bold">134.</span> Perlman JA, et al. <span class="Italics">J Chron Dis.</span> 1985;38(Oct):857. <span class="Bold">135.</span> Powell MG, et al. <span class="Italics">Obstet Gynecol.</span> 1984;63(June):764. <span class="Bold">136.</span> Wynn V, et al. <span class="Italics">Lancet.</span> 1966;2(Oct 1):720. <span class="Bold">137.</span> Fisch IR, et al. <span class="Italics">JAMA.</span> 1977;237(June 6):2499. <span class="Bold">138.</span> Kay CR. <span class="Italics">Lancet.</span> 1977;1(March 19):624. <span class="Bold">139.</span> Laragh JH. <span class="Italics">Am J Obstet Gynecol.</span> 1976;126(Sept 1):141. <span class="Bold">140.</span> Ramcharan S. In: Garattini S, Berendes HW, eds. <span class="Italics">Pharmacology of Steroid Contraceptive Drugs.</span> New York, NY: Raven Press; 1977:277-288. <span class="Bold">141.</span> Laumas KR, et al. <span class="Italics">Am J Obstet Gynecol.</span> 1967;98(June 1):411. <span class="Bold">142.</span> Saxena BN, et al. <span class="Italics">Contraception.</span> 1977;16(Dec):605. <span class="Bold">143.</span> Nilsson S, et al. <span class="Italics">Contraception.</span> 1978;17(Feb):131. <span class="Bold">144.</span> Washington AE, et al. <span class="Italics">JAMA. </span>1985;253(April 19):2246. <span class="Bold">145.</span> Louv WC, et al. <span class="Italics">Am J Obstet Gynecol.</span> 1989;160(Feb):396. <span class="Bold">146.</span> Francis WG, et al. <span class="Italics">Can Med Assoc J.</span> 1965;92(Jan 23):191. <span class="Bold">147.</span> Verhulst HL, et al. <span class="Italics">J Clin Pharmacol. </span>1967:7(Jan-Feb):9. <span class="Bold">148.</span> Ory HW, <span class="Italics">Fam Plann Perspect.</span> 1982;14(July-Aug):182. <span class="Bold">149.</span> Ory HW, et al. <span class="Italics">Making Choices: Evaluating the Health Risks and Benefits of Birth Control Methods.</span> New York, NY: The Alan Guttmacher Institute; 1983. <span class="Bold">150.</span> Palmer JR, et al. <span class="Italics">Am J Epidemiol. </span>1989;130(Nov):878. <span class="Bold">151.</span> Romieu I, et al. <span class="Italics">J Natl Cancer Inst. </span>1989;81(Sept):1313. <span class="Bold">152.</span> Porter JB, et al. <span class="Italics">Obstet Gynecol. </span>1987;70(July):29. <span class="Bold">153.</span> Olsson H, et al. <span class="Italics">Cancer Detect Prev.</span> 1991;15:265. <span class="Bold">154.</span> Delgado-Rodriguez M, et al. <span class="Italics">Rev Epidém Santé Publ.</span> 1991;39:165. <span class="Bold">155.</span> Clavel F, et al. <span class="Italics">Int J Epidemiol.</span> 1991;20(March):32. <span class="Bold">156.</span> Brinton LA, et al. <span class="Italics">JNCI.</span> 1995;87(June 7):827. <span class="Bold">157.</span> Thomas DB, et al. <span class="Italics">Br J Cancer.</span> 1992;65(January):108. <span class="Bold">158.</span> Thomas DB, et al. <span class="Italics">Cancer Causes Cont.</span> 1991;2(Nov):389. <span class="Bold">159.</span> Weinstein AL, et al. <span class="Italics">Epidemiology.</span> 1991;2(Sept):353. <span class="Bold">160.</span> Ranstam J, et al. <span class="Italics">Anticancer Res.</span> 1991;11(Nov-Dec):2043. <span class="Bold">161.</span> Ursin G. et al. <span class="Italics">Epidemiology.</span> 1992;3(Sept):414. <span class="Bold">162.</span> White E, et al. <span class="Italics">JNCI.</span> 1994;86(April 6):505. <span class="Bold">163.</span> Mann R, et al. <span class="Italics">Oral contraceptives and Breast Cancer.</span> Park Ridge, NJ: The Parthenon Publishing Group Inc.; 1990. <span class="Bold">164.</span> Institute of Medicine. Committee on the Relationship Between Oral Contraceptives and Breast Cancer. <span class="Italics">Oral Contraceptives and Breast Cancer.</span> Washington, DC: National Academy Press; 1991. <span class="Bold">165.</span> Harlap S. <span class="Italics">J Reprod Med.</span> 1991;36(May):374. <span class="Bold">166.</span> Rushton L, et al. <span class="Italics">Br J Obstet Gynaecol.</span> 1992;99(March):239. <span class="Bold">167.</span> Colditz G. <span class="Italics">Cancer.</span> 1993;71(Feb 15 suppl):1480.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e5a4ded0-2c67-4056-974e-ddc0fc4e15fa"></a><a name="section-13"></a><p></p>
<h1><span class="Bold">BRIEF SUMMARY OF PATIENT WARNINGS</span></h1>
<p class="First"> <span class="Bold">This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>.</span></p>
<p><span class="Italics">In the detailed leaflet, “What You Should Know About Oral Contraceptives,? which you have</span></p>
<table>
<col>
<col>
<tbody class="Headless"><tr class="First Last">
<td class="Lrule" valign="top"> <span class="Bold">Cigarette smoking increases the risk of serious adverse effects on the heart and blood vessels from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.</span>
</td>
<td class="Rrule" valign="top"> </td>
</tr></tbody>
</table>
<p><span class="Italics"> received, the risks and benefits of oral contraceptives are discussed in much more detail. That leaflet also provides information on other forms of contraception. </span><span class="Bold"><span class="Italics">Please take time to read it carefully for it may have been recently revised.</span></span></p>
<p><span class="Italics">If you have any questions or problems regarding this information, contact your doctor.</span></p>
<p>Oral contraceptives, also known as “birth control pills? or “the pill,? are taken to prevent pregnancy and, when taken correctly, have a failure rate of about 1% per year when used without missing any pills. The typical failure rate of large numbers of pill users is less than 3% per year when women who miss pills are included. However, forgetting to take pills considerably increases the chances of pregnancy.</p>
<p>For most women, oral contraceptives are free of serious or unpleasant side effects. However, oral contraceptive use is associated with certain serious diseases or conditions that can cause severe <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, though rarely. There are some women who are at high risk of developing certain serious diseases that can be life-threatening or may cause temporary or permanent <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>. The risks associated with taking oral contraceptives increase significantly if you:</p>
<ul class="Disk">
<li><p class="First">smoke, or</p></li>
<li><p class="First">have high blood pressure, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, or are overweight, or</p></li>
<li><p class="First">have or have had <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">clotting disorders</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> (<span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pains</span> on exertion), cancer of the breast or sex organs, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (yellowing of the skin or whites of the eyes), or malignant (cancerous) or benign (noncancerous) <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span>.</p></li>
</ul>
<p>Women should not use oral contraceptives if they suspect they are pregnant or if they have unexplained <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>.</p>
<p>Most side effects of the pill are not serious. The most common effects are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> between menstrual periods, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>, and difficulty wearing contact lenses. These side effects, especially <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, may subside within the first three months of use.</p>
<p>Proper use of oral contraceptives requires that they be taken under your doctor’s continuing supervision, because they can be associated with serious side effects. The serious side effects of the pill occur very infrequently, especially if you are in good health and are young. However, you should know that the following medical conditions have been associated with or made worse by the pill, and that certain of the risks may persist after use of the pill has been discontinued:</p>
<ol class="Arabic">
<li><p class="First">Blood clots in the legs, arms, lungs, heart (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>), eyes, abdomen, or elsewhere in the body. As mentioned above, smoking increases the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> and subsequent serious medical consequences.</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>, due to a blood clot, or to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the brain (<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>) as a result of bursting of a blood vessel. <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> can lead to <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> in all or part of the body, or to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Liver tumors</span>, which may rupture and cause severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. A possible, but not definite, association has also been found with the pill and liver cancer. However, with or without use of the pill, liver cancers are extremely rare in the United States.</p></li>
<li><p class="First">High blood pressure, although blood pressure ordinarily, but not always, returns to original levels when the pill is stopped.</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span>, which might require surgery.</p></li>
</ol>
<p>The symptoms associated with these serious side effects are discussed in the detailed leaflet given to you with your supply of pills. Notify your doctor or health care provider if you notice any unusual physical disturbances while taking the pill. In addition, you should be aware that drugs such as antiepileptics, antibiotics (especially rifampin), as well as certain other drugs, may decrease oral contraceptive effectiveness.</p>
<p>There is a conflict among studies regarding breast cancer and oral contraceptive use. Some studies have reported an increase in the risk of developing breast cancer, particularly at a younger age. This increased risk appears to be related to duration of use. The majority of studies have found no overall increase in the risk of developing breast cancer. Some studies have found an increase in the incidence of cancer of the cervix in women who use oral contraceptives. However, this finding may be related to factors other than the use of oral contraceptives. There is insufficient evidence to rule out the possibility that pills may cause such cancers.</p>
<p>Taking the pill may provide some important non-contraceptive benefits. These include less painful menstruation, less menstrual blood loss and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, less risk of <span class="product-label-link" type="condition" conceptid="197236" conceptname="Uterine leiomyoma">fibroids</span>, <span class="product-label-link" type="condition" conceptid="4003306" conceptname="Infection of pelvis">pelvic infections</span>, and noncancerous breast disease, and less risk of cancer of the ovary and of the lining of the uterus (womb).</p>
<p>Be sure to discuss any medical condition you may have with your health care provider. He or she will take a medical and family history before prescribing oral contraceptives and will also examine you. The physical examination may be delayed to another time if you request it and the health care provider believes that it is a good medical practice to postpone it. You should be re-examined at least once a year while taking oral contraceptives. The detailed patient information leaflet gives you further information that you should read and discuss with your health care provider.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_ec24cb5b-ec0d-4dd4-8e3c-df1e59a5f5ff"></a><a name="section-14"></a><p></p>
<h1><span class="Bold">DETAILED PATIENT LABELING:</span></h1>
<p class="First"><span class="Bold">WHAT YOU SHOULD KNOW ABOUT ORAL CONTRACEPTIVES</span></p>
<p><span class="Bold">This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>.</span></p>
<p><span class="Bold">INTRODUCTION</span></p>
<p>You should not use Zovia 1/50E, which contains higher doses of estrogen than other oral contraceptives, unless specifically recommended by your health care provider.</p>
<p>It is important that any woman who considers using an oral contraceptive understand the risks involved. Although the oral contraceptives have important advantages over other methods of contraception, they have certain risks that no other method has. Only you and your physician can decide whether the advantages are worth these risks. This leaflet will tell you about the most important risks. It will explain how you can help your doctor prescribe the pill as safely as possible by telling him/her about yourself and being alert for the earliest signs of trouble. And it will tell you how to use the pill properly so that it will be as effective as possible. THERE IS MORE DETAILED INFORMATION AVAILABLE IN THE LEAFLET PREPARED FOR DOCTORS. Your pharmacist can show you a copy; you may need your doctor’s help in understanding parts of it.</p>
<p>This leaflet is not a replacement for a careful discussion between you and your health care provider. You should discuss the information provided in this leaflet with him or her, both when you first start taking the pill and during your revisits. You should also follow your health care provider’s advice with regard to regular check-ups while you are on the pill.</p>
<p>If you do not have any of the conditions listed below and are thinking about using oral contraceptives, to help you decide, you need information about the advantages and risks of oral contraceptives and of other contraceptive methods as well. This leaflet describes the advantages and risks of oral contraceptives. Except for sterilization, the intrauterine device (IUD), and abortion, which have their own specific risks, the only risks of other methods are those due to pregnancy should the method fail. Your doctor can answer questions you may have with respect to other methods of contraception, and further questions you may have on oral contraceptives after reading this leaflet.</p>
<p><span class="Bold">WHAT ARE ORAL CONTRACEPTIVES?</span></p>
<p>The most common type of oral contraceptive, often simply called “the pill,? is a combination of estrogen and progestogen, the two kinds of female hormones. The amount of estrogen and progestogen can vary, but the amount of estrogen is more important because both the effectiveness and some of the dangers of the pill have been related to the amount of estrogen. The pill works principally by preventing release of an egg from the ovary during the cycle in which the pills are taken.</p>
<p><span class="Bold">EFFECTIVENESS OF ORAL CONTRACEPTIVES</span></p>
<p>The pill is one of the most effective methods of birth control. When they are taken correctly, without missing any pills, the chance of becoming pregnant is less than 1% (1 pregnancy per 100 women per year of use) when used perfectly, without missing any pills. Typical failure rates are actually about 3% per year. The chance of becoming pregnant increases with each missed pill during a menstrual cycle.</p>
<p>In comparison, typical failure rates for other methods of birth control during the first year of use are as follows:</p>
<table>
<caption><span>Percentage of women experiencing an <span class="product-label-link" type="condition" conceptid="4307820" conceptname="Unplanned pregnancy">unintended pregnancy</span> during the first year of typical use and the first year of perfect use of contraception and the percentage continuing use at the end of the first year. United States.</span></caption>
<col>
<col>
<col>
<col>
<thead>
<tr class="First">
<td class="Toprule" valign="top"> </td>
<td class="Toprule" align="center" colspan="2" valign="top"> <span class="Bold">% of women experiencing</span>
</td>
<td class="Toprule" align="center" valign="top"> <span class="Bold">% of women</span>
</td>
</tr>
<tr>
<td valign="top"> </td>
<td align="center" colspan="2" valign="top"> <span class="Bold">an <span class="product-label-link" type="condition" conceptid="4307820" conceptname="Unplanned pregnancy">unintended pregnancy</span></span>
</td>
<td align="center" valign="top"> <span class="Bold">continuing</span>
</td>
</tr>
<tr>
<td valign="top"> </td>
<td align="center" colspan="2" valign="top"> <span class="Bold">within the first year of use</span>
</td>
<td align="center" valign="top"> <span class="Bold">use at one</span>
</td>
</tr>
<tr>
<td valign="top"> </td>
<td valign="top"> </td>
<td valign="top"> </td>
<td align="center" valign="top"> <span class="Bold">year </span><span class="Bold"><span class="Italics"><span class="Sup">(C)</span></span></span>
</td>
</tr>
<tr>
<td valign="top"> </td>
<td class="Botrule" valign="top"> </td>
<td class="Botrule" valign="top"> </td>
<td valign="top"> </td>
</tr>
<tr>
<td valign="top"> <span class="Bold">Method</span>
</td>
<td class="Toprule" align="center" valign="top"> <span class="Bold">Typical use </span><span class="Bold"><span class="Italics"><span class="Sup">(A)</span></span></span>
</td>
<td class="Toprule" align="center" valign="top"> <span class="Bold">Perfect use </span><span class="Bold"><span class="Italics"><span class="Sup">(B)</span></span></span>
</td>
<td valign="top"> </td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"> <span class="Bold">(1)</span>
</td>
<td class="Botrule" align="center" valign="top"> <span class="Bold">(2)</span>
</td>
<td class="Botrule" align="center" valign="top"> <span class="Bold">(3)</span>
</td>
<td class="Botrule" align="center" valign="top"> <span class="Bold">(4)</span>
</td>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Botrule" colspan="4" valign="top"> Source: Trussell J, Contraceptive efficacy. In Hatcher RA, Trussell J, Stewart F, Cates W, Stewart GK, Kowal D, Guest F, <span class="Italics">Contraceptive Technology: Seventeenth Revised Edition. </span>New York NY: Irvington Publishers, 1998, in press. <span class="Sup">1</span>
</td></tr>
<tr><td colspan="4" valign="top"> <span class="Italics"><span class="Sup">(A)</span></span> Among <span class="Italics">typical </span>couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason.</td></tr>
<tr><td colspan="4" valign="top"> <span class="Italics"><span class="Sup">(B)</span></span> Among couples who initiate use of a method (not necessarily for the first time) and who use it <span class="Italics">perfectly </span>(both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason.</td></tr>
<tr><td colspan="4" valign="top"> <span class="Italics"><span class="Sup">(C)</span></span> Among couples attempting to avoid pregnancy, the percentage who continue to use a method for one year.</td></tr>
<tr><td colspan="4" valign="top"> <span class="Italics"><span class="Sup">(D)</span></span> The percents becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. Among such populations, about 89% become pregnant within one year. This estimate was lowered slightly (to 85%) to represent the percent who would become pregnant within one year among women now relying on reversible methods of contraception if they abandoned contraception altogether.</td></tr>
<tr><td colspan="4" valign="top"> <span class="Italics"><span class="Sup">(E)</span></span> Foams, creams, gels, vaginal suppositories, and vaginal film.</td></tr>
<tr><td colspan="4" valign="top"> <span class="Italics"><span class="Sup">(F)</span></span> Cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal body temperature in the post-ovulatory phases.</td></tr>
<tr><td colspan="4" valign="top"> <span class="Italics"><span class="Sup">(G)</span></span> With spermicidal cream or jelly.</td></tr>
<tr><td colspan="4" valign="top"> <span class="Italics"><span class="Sup">(H)</span></span> Without spermicides.</td></tr>
<tr><td colspan="4" valign="top"> <span class="Italics"><span class="Sup">(I)</span></span> The treatment schedule is one dose within 72 hours after unprotected intercourse and a second dose 12 hours after the first dose. The Food and Drug Administration has declared the following brands of oral contraceptives to be safe and effective for emergency contraception: Ovral (1 dose is 2 white pills), Alesse (1 dose is 5 pink pills), Nordette or Levlen (1 dose is 2 light-orange pills), Lo/Ovral (1 dose is 4 white pills), Triphasil or Tri-Levlen (1 dose is 4 yellow pills).</td></tr>
<tr class="Last"><td colspan="4" valign="top"> <span class="Italics"><span class="Sup">(J)</span></span> However, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is reduced, bottle feeds are introduced, or the baby reaches six months of age.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td valign="top"> Chance <span class="Italics"><span class="Sup">(D)</span></span>
</td>
<td align="center" valign="top"> 85</td>
<td align="center" valign="top"> 85</td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top"> Spermicides <span class="Italics"><span class="Sup">(E)</span></span>
</td>
<td align="center" valign="top"> 26</td>
<td align="center" valign="top"> 6</td>
<td align="center" valign="top"> 40</td>
</tr>
<tr>
<td valign="top"> Periodic abstinence</td>
<td align="center" valign="top"> 25</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> 63</td>
</tr>
<tr>
<td valign="top">   Calendar</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> 9</td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top">   Ovulation method</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> 3</td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top">   Sympto-thermal <span class="Italics"><span class="Sup">(F)</span></span>
</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> 2</td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top">   Post-ovulation</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> 1</td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top"> Withdrawal</td>
<td align="center" valign="top"> 19</td>
<td align="center" valign="top"> 4</td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top"> Cap <span class="Italics"><span class="Sup">(G)</span></span>
</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top">   Parous women</td>
<td align="center" valign="top"> 40</td>
<td align="center" valign="top"> 26</td>
<td align="center" valign="top"> 42</td>
</tr>
<tr>
<td valign="top">   Nulliparous women</td>
<td align="center" valign="top"> 20</td>
<td align="center" valign="top"> 9</td>
<td align="center" valign="top"> 56</td>
</tr>
<tr>
<td valign="top"> Sponge</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top">   Parous women</td>
<td align="center" valign="top"> 40</td>
<td align="center" valign="top"> 20</td>
<td align="center" valign="top"> 42</td>
</tr>
<tr>
<td valign="top">   Nulliparous women</td>
<td align="center" valign="top"> 20</td>
<td align="center" valign="top"> 9</td>
<td align="center" valign="top"> 56</td>
</tr>
<tr>
<td valign="top"> Diaphragm <span class="Italics"><span class="Sup">(G)</span></span>
</td>
<td align="center" valign="top"> 20</td>
<td align="center" valign="top"> 6</td>
<td align="center" valign="top"> 56</td>
</tr>
<tr>
<td valign="top"> Condom <span class="Italics"><span class="Sup">(H)</span></span>
</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top">   Female (Reality)</td>
<td align="center" valign="top"> 21</td>
<td align="center" valign="top"> 5</td>
<td align="center" valign="top"> 56</td>
</tr>
<tr>
<td valign="top">   Male</td>
<td align="center" valign="top"> 14</td>
<td align="center" valign="top"> 3</td>
<td align="center" valign="top"> 61</td>
</tr>
<tr>
<td valign="top"> Pill</td>
<td align="center" valign="top"> 5</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> 71</td>
</tr>
<tr>
<td valign="top">   Progestin only</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> 0.5</td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top">   Combined</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> 0.1</td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top"> IUD</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top">   Progesterone T</td>
<td align="center" valign="top"> 2.0</td>
<td align="center" valign="top"> 1.5</td>
<td align="center" valign="top"> 81</td>
</tr>
<tr>
<td valign="top">   Copper T 380A</td>
<td align="center" valign="top"> 0.8</td>
<td align="center" valign="top"> 0.6</td>
<td align="center" valign="top"> 78</td>
</tr>
<tr>
<td valign="top">   LNg 20</td>
<td align="center" valign="top"> 0.1</td>
<td align="center" valign="top"> 0.1</td>
<td align="center" valign="top"> 81</td>
</tr>
<tr>
<td valign="top"> Injection (Depo-Provera)</td>
<td align="center" valign="top"> 0.3</td>
<td align="center" valign="top"> 0.3</td>
<td align="center" valign="top"> 70</td>
</tr>
<tr>
<td valign="top"> Implant (Norplant</td>
<td align="center" valign="top"> 0.05</td>
<td align="center" valign="top"> 0.05</td>
<td align="center" valign="top"> 88</td>
</tr>
<tr>
<td valign="top">   and Norplant-2)</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top"> Female sterilization</td>
<td align="center" valign="top"> 0.5</td>
<td align="center" valign="top"> 0.5</td>
<td align="center" valign="top"> 100</td>
</tr>
<tr>
<td valign="top"> Male sterilization</td>
<td align="center" valign="top"> 0.15</td>
<td align="center" valign="top"> 0.10</td>
<td align="center" valign="top"> 100</td>
</tr>
<tr>
<td class="Botrule" valign="top"> </td>
<td class="Botrule" valign="top"> </td>
<td class="Botrule" valign="top"> </td>
<td class="Botrule" valign="top"> </td>
</tr>
<tr><td class="Toprule" colspan="4" valign="top"> <span class="Bold">Emergency Contraceptive Pills:</span> Treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%. <span class="Italics"><span class="Sup">(I)</span></span>
</td></tr>
<tr class="Last"><td class="Botrule" colspan="4" valign="top"> <span class="Bold">Lactational <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span> Method:</span> LAM is a highly effective, <span class="Italics">temporary </span>method of contraception. <span class="Italics"><span class="Sup">(J)</span></span>
</td></tr>
</tbody>
</table>
<p><span class="Bold">WHO SHOULD NOT TAKE ORAL CONTRACEPTIVES</span></p>
<table>
<col>
<col>
<tbody class="Headless"><tr class="First Last">
<td class="Lrule" valign="top"> <span class="Bold">Cigarette smoking increases the risk of serious adverse effects on the heart and blood vessels from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.</span>
</td>
<td class="Rrule" valign="top"> </td>
</tr></tbody>
</table>
<p>Some women should not use the pill. For example, you should not take the pill if you are pregnant or think you may be pregnant. You should also not use the pill if you have any of the following conditions:</p>
<ul class="Disk">
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (blood clot or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> in the brain), currently or in the past.</p></li>
<li><p class="First">Blood clots in the legs (<span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>), lungs (<span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>), eyes, or elsewhere in the body, currently or in the past.</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> (<span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>), currently or in the past.</p></li>
<li><p class="First">Known or suspected breast cancer or cancer of the lining of the uterus (womb), cervix, or vagina, currently or in the past.</p></li>
<li><p class="First">Unexplained <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> (until a diagnosis is reached by your doctor).</p></li>
<li><p class="First">Yellowing of the whites of the eyes or of the skin (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>) during pregnancy or during previous use of the pill.</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Liver tumor</span> (whether cancerous or not), currently or in the past.</p></li>
<li><p class="First">Known or suspected pregnancy (one or more menstrual periods missed).</p></li>
</ul>
<p>Tell your health care provider if you have ever had any of these conditions. He or she can recommend a safer method of birth control.</p>
<p><span class="Bold">OTHER CONSIDERATIONS BEFORE TAKING ORAL CONTRACEPTIVES</span></p>
<p>Tell your health care provider if you have or have had any of the following conditions, as he or she will want to watch them closely or they might cause him or her to suggest using another method of contraception:</p>
<ul class="Disk">
<li><p class="First">Breast <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> (lumps), fibrocystic disease (<span class="product-label-link" type="condition" conceptid="78473" conceptname="Solitary cyst of breast">breast cysts</span>), abnormal mammograms (x-ray pictures of the breast), or abnormal Pap smears</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></p></li>
<li><p class="First">High blood pressure</p></li>
<li><p class="First">High blood <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> or triglycerides</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> or other <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> or <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span></p></li>
<li><p class="First">Mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></p></li>
<li><p class="First">Gallbladder, heart, or kidney disease</p></li>
<li><p class="First">History of scanty or irregular menstrual periods</p></li>
<li><p class="First">Problems during a prior pregnancy</p></li>
<li><p class="First">Fibroid tumors of the womb</p></li>
<li><p class="First">History of <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (yellowing of the whites of the eyes or of the skin)</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="312349" conceptname="Venous varices">Varicose veins</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span></p></li>
<li><p class="First">Plans for elective surgery</p></li>
</ul>
<p>Women with any of these conditions should be checked often by their health care provider if they choose to use oral contraceptives.</p>
<p>Also, be sure to tell your doctor if you smoke or are on any medications.</p>
<p><span class="Bold">RISKS OF TAKING ORAL CONTRACEPTIVES</span></p>
<p><span class="Bold">1. Risk of developing blood clots.</span> Blood clots and blockage of blood vessels are the most serious side effects of taking oral contraceptives. In particular, a clot in the legs can cause <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> and a clot that travels to the lungs can cause a sudden blocking of the vessel carrying blood to the lungs. Rarely, clots occur in the blood vessels of the eye and may cause <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">double vision</span>, or impaired vision.</p>
<p>If you take oral contraceptives and need elective surgery, need to stay in bed for a prolonged illness, or have recently delivered a baby, you may be at risk of developing blood clots. You should consult your doctor about stopping oral contraceptives 3 to 4 weeks before surgery and not taking oral contraceptives for 2 weeks after surgery or during bed rest. You should also not take oral contraceptives soon after delivery of a baby. It is advisable to wait for at least 4 weeks after delivery if you are not breast feeding. If you are breast feeding, you should wait until you have weaned your child before using the pill. (See also the section on <a href="#LINK_9d553461-61f6-43f5-9ad9-d1746539e10c">Breast feeding</a> in <span class="Bold">GENERAL PRECAUTIONS</span>.)</p>
<p>The risk of circulatory disease in oral contraceptive users may be higher in users of high-dose pills and may be greater with longer duration of oral contraceptive use. In addition, some of these increased risks may continue for a number of years after stopping oral contraceptives. The risk of abnormal blood clotting increases with age in both users and nonusers of oral contraceptives, but the increased risk from the oral contraceptive appears to be present at all ages. For women aged 20 to 44 it is estimated that about 1 in 2,000 using oral contraceptives will be hospitalized each year because of abnormal clotting. Among nonusers in the same age group, about 1 in 20,000 would be hospitalized each year. For oral contraceptive users in general, it has been estimated that in women between the ages of 15 and 34, the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to a circulatory disorder is about 1 in 12,000 per years, whereas for nonusers the rate is about 1 in 50,000 per year. In the age group 35 to 44, the risk is estimated to be about 1 in 2,500 per year for oral contraceptive users and about 1 in 10,000 per year for nonusers.</p>
<p><span class="Bold">2. <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart attacks</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>.</span> Oral contraceptives may increase the tendency to develop <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> (stoppage by blood clots or rupture of blood vessels of the brain) and <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span> (blockage of blood vessels of the heart). Any of these conditions can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or permanent <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>.</p>
<p>Smoking greatly increases the possibility of suffering <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>. Furthermore, smoking and the use of oral contraceptives greatly increases the chances of developing and dying of heart disease.</p>
<p><span class="Bold">3. <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span>.</span> Oral contraceptive users probably have a greater risk than non-users of having <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>, although this risk may be related to pills containing high doses of estrogens.</p>
<p><span class="Bold">4. <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Liver tumors</span>.</span> In rare cases, oral contraceptives can cause benign but dangerous <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span>. These benign tumors can rupture and cause fatal internal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. In addition, a possible but not definite association has been found with the pill and liver cancers in several studies, in which a few women who developed these very rare cancers were found to have used oral contraceptives for long periods. However, liver cancers are rare.</p>
<p><span class="Bold">5. Cancer of the reproductive organs and breasts.</span> There is conflict among studies regarding breast cancer and oral contraceptive use. Some studies have reported an increase in the risk of developing breast cancer, particularly at a younger age. This increased risk appears to be related to duration of use. The majority of studies have found no overall increase in the risk of developing breast cancer. Women who use oral contraceptives and have a strong family history of breast cancer or who have had breast <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> or abnormal mammograms should be closely followed by their doctors.</p>
<p>Some studies have found an increase in the incidence of cancer of the cervix in women who use oral contraceptives. However, this finding may be related to factors other than the use of oral contraceptives. There is insufficient evidence to rule out the possibility that pills may cause such cancers.</p>
<p><span class="Bold">ESTIMATED RISK OF <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span></span><span class="Bold"><br></span><span class="Bold">FROM BIRTH CONTROL METHOD OR PREGNANCY</span></p>
<p>All methods of birth control and pregnancy are associated with a risk of developing certain diseases that may lead to <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. An estimate of the number of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> associated with different methods of birth control and pregnancy has been calculated and is shown in the following table.</p>
<table>
<caption><span>Annual number of birth-related or method-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> associated with control of fertility per 100,000 nonsterile women, by fertility control method according to age.</span></caption>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<thead>
<tr class="First">
<td colspan="2" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" colspan="2" valign="top"> <span class="Bold">Age</span>
</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td colspan="2" valign="top"> </td>
<td class="Botrule" align="center" valign="top"> </td>
<td class="Botrule" align="center" valign="top"> </td>
<td class="Botrule" align="center" valign="top"> </td>
<td class="Botrule" align="center" valign="top"> </td>
<td class="Botrule" align="center" valign="top"> </td>
<td class="Botrule" align="center" valign="top"> </td>
</tr>
<tr class="Last">
<td class="Botrule" colspan="2" valign="top"> <span class="Bold">Method of control</span>
</td>
<td class="Botrule Toprule" align="center" valign="top"> <span class="Bold">15-19</span>
</td>
<td class="Botrule Toprule" align="center" valign="top"> <span class="Bold">20-24</span>
</td>
<td class="Botrule Toprule" align="center" valign="top"> <span class="Bold">25-29</span>
</td>
<td class="Botrule Toprule" align="center" valign="top"> <span class="Bold">30-34</span>
</td>
<td class="Botrule Toprule" align="center" valign="top"> <span class="Bold">35-39</span>
</td>
<td class="Botrule Toprule" align="center" valign="top"> <span class="Bold">40-44</span>
</td>
</tr>
</thead>
<tfoot>
<tr class="First"><td colspan="8" valign="top"> * <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> are birth-related</td></tr>
<tr class="Last"><td colspan="8" valign="top"> ** <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> are method-related</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td colspan="2" valign="top"> No fertility control methods*</td>
<td align="center" valign="top"> 7.0</td>
<td align="center" valign="top"> 7.4</td>
<td align="center" valign="top"> 9.1</td>
<td align="center" valign="top"> 14.8</td>
<td align="center" valign="top"> 25.7</td>
<td align="center" valign="top"> 28.2</td>
</tr>
<tr>
<td colspan="2" valign="top"> Oral contraceptives</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td align="right" valign="top"> </td>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="4222303" conceptname="Non-smoker">nonsmoker</span>**</td>
<td align="center" valign="top"> 0.3</td>
<td align="center" valign="top"> 0.5</td>
<td align="center" valign="top"> 0.9</td>
<td align="center" valign="top"> 1.9</td>
<td align="center" valign="top"> 13.8</td>
<td align="center" valign="top"> 31.6</td>
</tr>
<tr>
<td align="right" valign="top"> </td>
<td valign="top"> smoker**</td>
<td align="center" valign="top"> 2.2</td>
<td align="center" valign="top"> 3.4</td>
<td align="center" valign="top"> 6.6</td>
<td align="center" valign="top"> 13.5</td>
<td align="center" valign="top"> 51.1</td>
<td align="center" valign="top"> 117.2</td>
</tr>
<tr>
<td colspan="2" valign="top"> IUD**</td>
<td align="center" valign="top"> 0.8</td>
<td align="center" valign="top"> 0.8</td>
<td align="center" valign="top"> 1.0</td>
<td align="center" valign="top"> 1.0</td>
<td align="center" valign="top"> 1.4</td>
<td align="center" valign="top"> 1.4</td>
</tr>
<tr>
<td colspan="2" valign="top"> Condom*</td>
<td align="center" valign="top"> 1.1</td>
<td align="center" valign="top"> 1.6</td>
<td align="center" valign="top"> 0.7</td>
<td align="center" valign="top"> 0.2</td>
<td align="center" valign="top"> 0.3</td>
<td align="center" valign="top"> 0.4</td>
</tr>
<tr>
<td colspan="2" valign="top"> Diaphragm/Spermicide*</td>
<td align="center" valign="top"> 1.9</td>
<td align="center" valign="top"> 1.2</td>
<td align="center" valign="top"> 1.2</td>
<td align="center" valign="top"> 1.3</td>
<td align="center" valign="top"> 2.2</td>
<td align="center" valign="top"> 2.8</td>
</tr>
<tr class="Last">
<td colspan="2" valign="top"> Periodic abstinence*</td>
<td align="center" valign="top"> 2.5</td>
<td align="center" valign="top"> 1.6</td>
<td align="center" valign="top"> 1.6</td>
<td align="center" valign="top"> 1.7</td>
<td align="center" valign="top"> 2.9</td>
<td align="center" valign="top"> 3.6</td>
</tr>
</tbody>
</table>
<p>In the above table, the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any birth control method is less than the risk of childbirth, except for oral contraceptive users over the age of 35 who smoke and pill users over the age of 40 even if they do not smoke. It can be seen in the table that for women aged 15 to 39, the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was highest with pregnancy (7-26 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> per 100,000 women, depending on age). Among pill users who do not smoke, the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was always lower than that associated with pregnancy for any age group, although over the age of 40, the risk increases to 32 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> per 100,000 women, compared to 28 associated with pregnancy at that age. However, for pill users who smoke and are over the age of 35, the estimated number of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> exceeds those for other methods of birth control. If a woman is over the age of 40 and smokes, her estimated risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> is four times higher (117/100,000 women) than the estimated risk associated with pregnancy (28/100,000) in that age group.</p>
<p>The suggestion that women over 40 who don’t smoke should not take oral contraceptives is based on information from older high-dose pills and on less selective use of pills than is practiced today. An Advisory Committee of the FDA discussed this issue in 1989 and recommended that the benefits of oral contraceptive use by healthy, nonsmoking women over 40 years of age may outweigh the possible risks. However, all women, especially older women, are cautioned to use the lowest dose pill that is effective.</p>
<p><span class="Bold">WARNING SIGNALS</span></p>
<p>If any of these adverse effects occur while you are taking oral contraceptives, call your doctor immediately:</p>
<ul class="Disk">
<li><p class="First">Sharp <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> up blood, or sudden <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> (indicating a possible blood clot in the lung).</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> in the calf (indicating a possible blood clot in the leg).</p></li>
<li><p class="First">Crushing <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or heaviness in the chest (indicating a possible <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>).</p></li>
<li><p class="First">Sudden severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>, disturbances of vision or speech, or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> in an arm or leg (indicating a possible <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>).</p></li>
<li><p class="First">Sudden partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> (indicating a possible blood clot in the blood vessels of the eye).</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">Breast lumps</span> (indicating possible breast cancer or fibrocystic disease of the breast). Ask your doctor or health care provider to show you how to examine your own breasts.</p></li>
<li><p class="First">Severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> or a <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> in the stomach area (indicating a possible ruptured <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumor</span>).</p></li>
<li><p class="First">Difficulty in sleeping, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, lack of energy, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, or change in mood (possibly indicating severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>).</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span> or a yellowing of the skin or eyeballs, accompanied frequently by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, loss of appetite, dark-colored urine, or light-colored bowel movements (indicating possible liver problems).</p></li>
<li><p class="First">Unusual <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>.</p></li>
<li><p class="First">Other unusual conditions.</p></li>
</ul>
<p><span class="Bold">SIDE EFFECTS OF ORAL CONTRACEPTIVES</span></p>
<p><span class="Bold">1. <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal bleeding</span>.</span></p>
<p><span class="Italics">Spotting.</span> This is a slight staining between your menstrual periods that may not even require a pad. Some women spot even though they take their pills exactly as directed. Many women spot although they have never taken the pills. Spotting does not mean that your ovaries are releasing an egg. Spotting may be the result of irregular pill-taking. Getting back on schedule will usually stop it.</p>
<p>If you should spot while taking the pills, you should not be alarmed, because spotting usually stops by itself within a few days. It seldom occurs after the first pill cycle. Consult your doctor if spotting persists for more than a few days or if it occurs after the second cycle.</p>
<p><span class="Italics">Unexpected (breakthrough) <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</span> Unexpected (breakthrough) <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> does not mean that your ovaries have released an egg. It seldom occurs, but when it does happen it is most common in the first pill cycle. It is a flow much like a regular period, requiring the use of a pad or tampon.</p>
<p>If you experience breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> use a pad or tampon and continue with your schedule. Usually your periods will become regular within a few cycles. Breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> will seldom bother you again.</p>
<p>Consult your doctor or health care provider if breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is heavy, does not stop within a week, or if it occurs after the second cycle.</p>
<p><span class="Bold">2. Contact lenses.</span> If you wear contact lenses and notice a change in vision or an inability to wear your lenses, contact your doctor or health care provider.</p>
<p><span class="Bold">3. <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> or raised blood pressure.</span> Oral contraceptives may cause <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>), with <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the fingers or ankles. If you experience <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, contact your doctor or health care provider. Some women develop high blood pressure while on the pill, which ordinarily, but not always, returns to the original levels when the pill is stopped. High blood pressure predisposes one to <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, kidney disease, and other diseases of the blood vessels.</p>
<p><span class="Bold">4. <span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">Melasma</span>.</span> A spotty darkening of the skin is possible, particularly of the face. This may persist after the pill is discontinued.</p>
<p><span class="Bold">5. Other side effects.</span> Other side effects may include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, change in appetite, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, loss of scalp hair, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginal infections</span>.</p>
<p>If any of these, or other, side effects occur, call your doctor or health care provider.</p>
<p><span class="Bold">GENERAL PRECAUTIONS</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2725fa16-2c6b-4f22-b48b-e59c2f1ae823"></a><a name="section-14.1"></a><p></p>
<h2><span class="Bold">1. Missed periods and use of oral contraceptives before or during early pregnancy.</span></h2>
<p class="First">Occasionally women who are taking the pill miss periods. It has been reported to occur as frequently as several times each year in some women, depending on various factors such as age and prior history (your doctor is the best source of information about this). The pill should not be used when you are pregnant or suspect you may be pregnant. Very rarely, women who are using the pill as directed become pregnant. The likelihood of becoming pregnant is higher if you occasionally miss one or two pills. Therefore, if you miss a period you should consult your physician before continuing to take the pill. If you miss a period, especially if you have not taken the pill regularly, you should use an alternative method of contraception until pregnancy has been ruled out; if you have missed more than one pill at any time, you should immediately start using an additional method of contraception and complete your pill cycle.</p>
<p>There is no conclusive evidence that oral contraceptive use is associated with an increase in <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> when taken inadvertently during early pregnancy. Previously, a few studies had reported that oral contraceptives might be associated with <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>, but these findings have not been seen in more recent studies. Nevertheless, oral contraceptives or any other drugs should not be used during pregnancy unless clearly necessary and prescribed by your doctor. You should check with your doctor about risks to your unborn child of any medication taken during pregnancy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9d553461-61f6-43f5-9ad9-d1746539e10c"></a><a name="section-14.2"></a><p></p>
<h2><span class="Bold">2. Breast feeding.</span></h2>
<p class="First">If you are breast feeding, consult your doctor before starting oral contraceptives. Some of the drug will be passed on to the child in the milk. A few adverse effects on the child have been reported, including yellowing of the skin (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>) and <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>. In addition, oral contraceptives may decrease the amount and quality of your milk. If possible, do not use oral contraceptives while breast feeding. You should use another method of contraception since breast feeding provides only partial protection from becoming pregnant and this partial protection decreases significantly as you breast feed for longer periods of time. You should consider starting oral contraceptives only after you have weaned your child completely.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_edf41804-59b8-441d-ae38-4dac81ace47d"></a><a name="section-14.3"></a><p></p>
<h2><span class="Bold">3. Laboratory tests.</span></h2>
<p class="First">If you are scheduled for any laboratory tests, tell your doctor you are taking birth control pills. Certain blood tests may be affected by birth control pills.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4de8e3f6-001e-4617-8d88-762675148644"></a><a name="section-14.4"></a><p></p>
<h2><span class="Bold">4. Drug interactions.</span></h2>
<p class="First">Certain drugs may interact with birth control pills to make them less effective in preventing pregnancy or cause an increase in breakthrough <br><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Such drugs include rifampin, drugs used for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> such as barbiturates (for example, phenobarbital) and phenytoin (Dilantin is one <br>brand of this drug), phenylbutazone (Butazolidin is one brand), Rezulin (troglitazone) a hypoglycemic, and possibly certain antibiotics. You may <br>need to use additional contraception when you take drugs that can make oral contraceptives less effective.</p>
<p>Oral contraceptives may have an influence upon the way other drugs act. Check with your doctor if you are taking <span class="Italics">any </span>other drugs while you are <br>on the pill.</p>
<p><span class="Bold">HOW TO TAKE THE PILL</span></p>
<p><span class="Bold">IMPORTANT POINTS TO REMEMBER</span></p>
<p><span class="Underline">BEFORE</span> YOU START TAKING YOUR PILLS:</p>
<ol class="Arabic">
<li>
<p class="First">BE SURE TO READ THESE DIRECTIONS:</p>
<ul class="Circle">
<li><p class="First">Before you start taking your pills.</p></li>
<li><p class="First">Anytime you are not sure what to do.</p></li>
</ul>
</li>
<li><p class="First">THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME.<br>If you miss pills you could get pregnant. This includes starting the pack late.<br>The more pills you miss, the more likely you are to get pregnant.</p></li>
<li><p class="First">MANY WOMEN HAVE SPOTTING OR LIGHT <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span>, OR MAY FEEL SICK TO THEIR STOMACH DURING THE FIRST 1-3 PACKS OF PILLS.<br>If you feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If it doesn’t go away, check with your doctor <br>or clinic.</p></li>
<li><p class="First">MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span>, even when you make up these missed pills.<br>On the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach.</p></li>
<li><p class="First">IF YOU HAVE <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">VOMITING</span> OR <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">DIARRHEA</span>, for any reason, or IF YOU TAKE SOME MEDICINES, including some antibiotics, your pills may not <br>work as well.<br>Use a backup method (such as condoms, foam, or sponge) until you check with your doctor or clinic.</p></li>
<li><p class="First">IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your doctor or clinic about how to make pill-taking easier or about using <br>another method of birth control.</p></li>
<li><p class="First">IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS LEAFLET, call your doctor or clinic.</p></li>
</ol>
<p><span class="Bold"><span class="Underline">BEFORE</span></span><span class="Bold"> YOU START TAKING YOUR PILLS</span></p>
<ol class="Arabic">
<li><p class="First">DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL.<br>It is important to take it at about the same time every day.</p></li>
<li><p class="First">LOOK AT YOUR PILL PACK TO SEE IF IT HAS 28 PILLS:<br>Your tablet dispenser consists of a case and a pill pack containing 28 pills. They are arranged in four numbered rows with the days of the <br>week printed above them.<br>The 28-pill pack has 21 “active? pills (with hormones- light pink or pink) to take for 3 weeks, followed by 1 week of reminder white pills <br>(without hormones). To remove a pill press down on it with the flat of your finger. The pill will drop through a hole in the bottom of the <br>dispenser.</p></li>
<li>
<p class="First">ALSO FIND:</p>
<ul class="Circle">
<li><p class="First">Where on the pack to start taking pills.</p></li>
<li>
<p class="First">In what order to take the pills (left to right).</p>
<p>Begin the <span class="Bold">28-pill pack</span> with the first pill in Row 1 and continue (→) across Row 1 (Week 1). Repeat for Row 2, Row 3, and finally <br>Row 4. Take all “active? pills (light pink or pink) before starting Row 4.<br><br><br>Zovia 1/35E 28-Pill Pack<br><br><br><img alt="Zovia 1/35E face card" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ae3c20e4-8850-4559-9ca3-06a98b3dabab&amp;name=ethynodiol-diacetate-and-ethiny-estradiol-tablets--4.jpg"><br><br><br>Zovia 1/50E 28-Pill Pack<br><br><br><img alt="zovia50E" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ae3c20e4-8850-4559-9ca3-06a98b3dabab&amp;name=ethynodiol-diacetate-and-ethiny-estradiol-tablets--5.jpg"></p>
</li>
</ul>
</li>
<li><p class="First">BE SURE YOU HAVE READY AT ALL TIMES:</p></li>
</ol>
<ul class="Disk">
<li><p class="First">ANOTHER KIND OF BIRTH CONTROL (such as condoms, foam, or sponge) to use as a backup in case you miss pills.</p></li>
<li><p class="First">AN EXTRA, FULL PILL PACK.</p></li>
</ul>
<p><span class="Bold">WHEN TO START THE </span><span class="Bold"><span class="Underline">FIRST</span></span><span class="Bold"> PACK OF PILLS</span></p>
<p>You have a choice of which day to start taking your first pack of pills. Decide with your doctor or clinic which is the best day for you. Pick a time <br>of day which will be easy to remember.</p>
<p><span class="Bold">DAY 1 START:</span></p>
<ol class="Arabic">
<li><p class="First">Take the first “active? pill (light pink or pink) of the first pack during <span class="Underline">the first 24 hours of your period.</span></p></li>
<li><p class="First">You will not need to use a backup method of birth control, since you are starting the pill at the beginning of your period.</p></li>
</ol>
<p><span class="Bold">SUNDAY START:</span></p>
<p>1. Take the first “active? pill (light pink or pink) of the first pack on the <span class="Underline">Sunday after your period starts</span>, even if you are still <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. If your period <br>begins on Sunday, start the pack that same day.</p>
<p>2. <span class="Underline">Use another method of birth control</span> as a backup method if you have sex anytime from the Sunday you start your first pack until the next Sunday <br>(7 days). Condoms, foam, or the sponge are good backup methods of birth control.</p>
<p><span class="Bold">WHAT TO DO DURING THE MONTH</span></p>
<ol class="Arabic">
<li>
<p class="First"><span class="Bold">TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY.</span></p>
<ul class="Circle">
<li><p class="First">Do not skip pills even if you are spotting or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> between monthly periods or feel sick to your stomach (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>).</p></li>
<li><p class="First">Do not skip pills even if you do not have sex very often.</p></li>
</ul>
</li>
<li><p class="First"><span class="Bold">WHEN YOU FINISH A PACK OR SWITCH YOUR BRAND OF 28-DAY PILLS:</span> Start the next pack on the day after your last “reminder? pill. <br>Do not wait any days between 28-day packs.</p></li>
</ol>
<p><span class="Bold">WHAT TO DO IF YOU MISS PILLS</span></p>
<p>If you <span class="Bold">MISS 1</span>“active? pill (light pink or pink):</p>
<ol class="Arabic">
<li><p class="First">Take it as soon as you remember. Take the next pill at your regular time. This means you may take 2 pills in 1 day.</p></li>
<li><p class="First">You do not need to use a backup birth control method if you have sex.</p></li>
</ol>
<p>If you <span class="Bold">MISS 2</span>“active? pills (light pink or pink) in a row in <span class="Bold">WEEK 1 OR WEEK 2</span> of your pack:</p>
<ol class="Arabic">
<li><p class="First">Take 2 pills on the day you remember and 2 pills the next day.</p></li>
<li><p class="First">Then take 1 pill a day until you finish the pack.</p></li>
<li><p class="First">You MAY BECOME PREGNANT if you have sex in the <span class="Underline">7 days</span> after you miss pills. You MUST use another birth control method (such as <br>condoms, foam, or sponge) as a backup for those 7 days.</p></li>
</ol>
<p>If you <span class="Bold">MISS 2</span>“active? pills (light pink or pink) in a row in <span class="Bold">THE 3rd WEEK:</span></p>
<ol class="Arabic">
<li><p class="First"><span class="Bold"><span class="Italics">If you are a Day 1 Starter:</span></span><br>THROW OUT the rest of the pill pack and start a new pack that same day.<br><span class="Bold"><span class="Italics">If you are a Sunday Starter:</span></span><br>Keep taking 1 pill every day until Sunday.<br>On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day.</p></li>
<li><p class="First">You may not have your period this month but this is expected. However, if you miss your period 2 months in a row, call your doctor or <br>clinic because you might be pregnant.</p></li>
<li><p class="First">You MAY BECOME PREGNANT if you have sex in the <span class="Underline">7 days</span> after you miss pills. You MUST use another birth control method (such as <br>condoms, foam, or sponge) as a backup for those 7 days.</p></li>
</ol>
<p>If you <span class="Bold">MISS 3 OR MORE</span>“active? pills (light pink or pink) in a row (during the first 3 weeks):</p>
<ol class="Arabic">
<li>
<p class="First"><span class="Bold"><span class="Italics">If you are a Day 1 Starter:</span></span></p>
<p>THROW OUT the rest of the pill pack and start a new pack of pills that same day.</p>
<p><span class="Bold"><span class="Italics">If you are a Sunday Starter:</span></span></p>
<p>Keep taking 1 pill every day until Sunday.</p>
<p>On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day.</p>
</li>
<li><p class="First">You may not have your period this month but this is expected. However, if you miss your period 2 months in a row, call your doctor or <br>clinic because you might be pregnant.</p></li>
<li><p class="First">You MAY BECOME PREGNANT if you have sex in the <span class="Underline">7 days</span> after you miss pills. You MUST use another birth control method (such as <br>condoms, foam, or sponge) as a backup for those 7 days.</p></li>
</ol>
<p><span class="Bold">A REMINDER FOR THOSE ON 28-DAY PACKS</span></p>
<p>If you forget any of the 7 white “reminder? pills in Week 4:</p>
<ul class="Disk">
<li><p class="First">THROW AWAY the pills you missed.</p></li>
<li><p class="First">Keep taking 1 pill each day until the pack is empty.</p></li>
<li><p class="First">You do not need a backup method.</p></li>
</ul>
<p><span class="Bold">FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT</span><span class="Bold"><br></span><span class="Bold">THE PILLS YOU HAVE MISSED</span></p>
<ul class="Disk">
<li><p class="First">Use a BACKUP METHOD of birth control anytime you have sex.</p></li>
<li><p class="First">KEEP TAKING ONE “ACTIVE? PILL EACH DAY until you can reach your doctor or clinic.</p></li>
</ul>
<p><span class="Bold">PREGNANCY DUE TO PILL FAILURE</span></p>
<p>The incidence of pill failure resulting in pregnancy is approximately 1% (i.e., one pregnancy per 100 women per year) if taken every day as <br>directed, but, because some women fail to follow the daily schedule, more typical failure rates are about 3%. If you become pregnant you should <br>discuss your pregnancy with your doctor.</p>
<p><span class="Bold">PREGNANCY AFTER STOPPING THE PILL</span></p>
<p>There may be some delay in becoming pregnant after you stop using oral contraceptives, especially if you had <span class="product-label-link" type="condition" conceptid="196168" conceptname="Irregular periods">irregular menstrual cycles</span> before <br>you used oral contraceptives. It may be advisable to postpone conception until you begin menstruating regularly once you have stopped taking the <br>pill and desire pregnancy.</p>
<p>There does not appear to be any increase in <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in newborn babies when pregnancy occurs after stopping the pill.</p>
<p><span class="Bold">OVERDOSAGE</span></p>
<p>Serious ill effects have not been reported following ingestion of large doses of oral contraceptives by young children. Overdosage may cause <br><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> in females. In case of overdosage, contact your health care provider, pharmacist or Poison Control Center.</p>
<p><span class="Bold">OTHER INFORMATION</span></p>
<p>Your health care provider will take a medical and family history before prescribing oral contraceptives and will also examine you. The physical <br>examination may be delayed to another time if you request it and the health care provider believes that it is a good medical practice to postpone it. <br>You should be re-examined at least once a year. Certain health problems or conditions in your medical or family history may require that your health<br>care provider see you more frequently while you are taking the pill. Be sure to keep all appointments with your health care provider because this is <br>a time to determine if there are early signs of side effects of oral contraceptive use.</p>
<p>Do not use the drug for any condition other than the one for which it was prescribed. This drug has been prescribed specifically for you; do not <br>give it to others who may want birth control pills.</p>
<p>This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually <br>transmitted diseases such as chlamydia, <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>, <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">genital warts</span>, <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B, and <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span>.</p>
<p><span class="Bold">HEALTH BENEFITS FROM ORAL CONTRACEPTIVES</span></p>
<p>In addition to preventing pregnancy, use of oral contraceptives may provide certain benefits. They are:</p>
<ul class="Disk">
<li><p class="First">Menstrual cycles may become more regular</p></li>
<li><p class="First">Blood flow during menstruation may be lighter and less iron may be lost. Therefore, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> due to <span class="product-label-link" type="condition" conceptid="4146209" conceptname="Iron deficiency">iron deficiency</span> is less likely to occur</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> or other symptoms during menstruation may be encountered less frequently</p></li>
<li><p class="First">Ectopic (tubal) pregnancy may occur less frequently</p></li>
<li><p class="First">Noncancerous <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span> or lumps in the breast may occur less frequently</p></li>
<li><p class="First">Acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> may occur less frequently</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="197236" conceptname="Uterine leiomyoma">Fibroids</span> of the uterus (womb) may occur less frequently</p></li>
<li><p class="First">Oral contraceptive use may provide some protection against developing two forms of cancer: cancer of the ovaries and cancer of the <br>lining of the uterus (womb)</p></li>
</ul>
<p>If you want more information about birth control pills, ask your doctor or pharmacist. They have a more technical leaflet called the Professional <br>Labeling, which you may wish to read. The Professional Labeling is also published in a book entitled <span class="Italics">Physicians’ Desk Reference, </span>available in <br>many book stores and public libraries.</p>
<p><span class="Bold">Keep this and all drugs out of the reach of children.</span></p>
<p><span class="Bold">Be certain to read new revisions of this leaflet.</span></p>
<p>Address medical inquiries to:<br>Watson Pharma, Inc.<br>Medical Communications<br>P.O. Box 1953<br>Morristown, NJ 07962-1953<br>800-272-5525</p>
<p>Manufactured by:<br>Watson Pharma, Inc.<br>A subsidiary of Watson Pharmaceuticals, Inc.<br>Corona, CA 92880 USA</p>
<p>Revised: August 2006        14602<br><br><span class="Bold">Zovia 1/35E-28<br>Zovia 1/50E-28<br></span>(Ethynodiol Diacetate and Ethinyl Estradiol Tablets USP)</p>
<p><span class="Bold"><span class="Italics">WATSON PHARMA</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_cacb9ee6-26d6-4faa-965f-37a57ef3feb4"></a><a name="section-15"></a><p></p>
<h1>Principal Display Panel - 1/35E</h1>
<p class="First"><span class="Bold">NDC 52544-383-31<br>Zovia<span class="Sup">®</span> 1/35E<br>(ethynodiol diacetate and ethiny estradiol tablets USP)</span></p>
<div class="Figure"><img alt="carton label 1/35E" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ae3c20e4-8850-4559-9ca3-06a98b3dabab&amp;name=ethynodiol-diacetate-and-ethiny-estradiol-tablets--6.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_73963681-fd53-4ba1-a8b7-0aae6ca3f419"></a><a name="section-16"></a><p></p>
<h1>Principal Display Panel - 1/50E</h1>
<p class="First"><span class="Bold">NDC 52544-384-28<br>Zovia<span class="Sup">®</span> 1/50E<br>(ethynodiol diacetate and ethiny estradiol tablets USP)</span></p>
<div class="Figure"><img alt="Carton label - 1/50E" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ae3c20e4-8850-4559-9ca3-06a98b3dabab&amp;name=ethynodiol-diacetate-and-ethiny-estradiol-tablets--7.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZOVIA 1/35E-28 		
					</strong><br><span class="contentTableReg">ethynodiol diacetate and ethinyl estradiol kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52544-383</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52544-383-31</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:52544-383-28</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem"> </td>
<td class="formItem">21 </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem"> </td>
<td class="formItem">7 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>ZOVIA 1/35E-28 		
					</strong><br><span class="contentTableReg">ethynodiol diacetate and ethinyl estradiol tablet</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ETHYNODIOL DIACETATE</strong> (ETHYNODIOL) </td>
<td class="formItem">ETHYNODIOL DIACETATE</td>
<td class="formItem">1 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ETHINYL ESTRADIOL</strong> (ETHINYL ESTRADIOL) </td>
<td class="formItem">ETHINYL ESTRADIOL</td>
<td class="formItem">35 ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLACRILIN POTASSIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C RED NO. 30</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Watson;383</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA072721</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>PLACEBO 		
					</strong><br><span class="contentTableReg">placebo tablet</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Watson;P</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA072721</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA072721</td>
<td class="formItem">12/30/1991</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZOVIA 1/50E-28 		
					</strong><br><span class="contentTableReg">ethynodiol diacetate and ethinyl estradiol kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52544-384</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52544-384-31</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:52544-384-28</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem"> </td>
<td class="formItem">21 </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem"> </td>
<td class="formItem">7 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>ZOVIA 1/50E-28 		
					</strong><br><span class="contentTableReg">ethynodiol diacetate and ethinyl estradiol tablet</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ETHYNODIOL DIACETATE</strong> (ETHYNODIOL) </td>
<td class="formItem">ETHYNODIOL DIACETATE</td>
<td class="formItem">1 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ETHINYL ESTRADIOL</strong> (ETHINYL ESTRADIOL) </td>
<td class="formItem">ETHINYL ESTRADIOL</td>
<td class="formItem">50 ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLACRILIN POTASSIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C RED NO. 30</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Watson;384</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA072723</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>PLACEBO 		
					</strong><br><span class="contentTableReg">placebo tablet</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Watson;P</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA072723</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA072723</td>
<td class="formItem">12/30/1991</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Watson Pharma, Inc.
							(106931488)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Catalent Pharma Solutions, LLC</td>
<td class="formItem"></td>
<td class="formItem">014167995</td>
<td class="formItem">ANALYSIS(52544-384, 52544-383)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Quality Chemical Laboratories</td>
<td class="formItem"></td>
<td class="formItem">071344167</td>
<td class="formItem">ANALYSIS(52544-384, 52544-383)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">SGS Life Science Services</td>
<td class="formItem"></td>
<td class="formItem">062491980</td>
<td class="formItem">ANALYSIS(52544-384, 52544-383)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Watson Laboratories, Inc.</td>
<td class="formItem"></td>
<td class="formItem">840054118</td>
<td class="formItem">ANALYSIS(52544-383, 52544-384), LABEL(52544-383, 52544-384), MANUFACTURE(52544-383, 52544-384), PACK(52544-383, 52544-384)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f5ef9b7a-e41b-4e50-a27d-4d65e17dc71b</div>
<div>Set id: ae3c20e4-8850-4559-9ca3-06a98b3dabab</div>
<div>Version: 5</div>
<div>Effective Time: 20131023</div>
</div>
</div> <div class="DistributorName">Watson Pharma, Inc.</div></p>
</body></html>
